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ABSTRACT
This dissertation is a synopsis of advancements in the field of ionic liquids and a group
of uniform materials based on organic salts (GUMBOS) in biomedical applications, especially
with regard to cancer research. The toxicity of chemotherapeutic agents to normal tissues and
drug resistance are a major concern in cancer treatment. In this dissertation, GUMBOS and
nanoGUMBOS as well as ionic liquids and nanodroplets are explored as possible
chemotherapeutic agents with minimal toxicity to normal cells.
In the first part of my dissertation, exploitation of ionic liquid chemistry to modulate
toxicity of rhodamine 6G is reported. Rhodamine 6G-based GUMBOS with varying counteranions that are stable under physiological conditions, display excellent fluorescence
photostability, and more importantly have tunable chemotherapeutic properties were
synthesized. In vitro studies indicate that the hydrophobic compounds of this series allow
production of nanoGUMBOS which are non-toxic to normal cells and toxic to cancer cells.
Furthermore, the anions, in combination with cations such as sodium, were observed to be
non-toxic to both normal and cancer cells. Thus, we demonstrate that both the cation and
anion play an extremely important and cooperative role in the anticancer properties of these
compounds.
In the second part, the concept of multifunctional nanoparticles is introduced and
exploited for theranostic applications. Nanoparticles possessing multiple properties such as
luminescence, magnetism, and cancer targeting, were synthesized and explored for use in
cancer therapy. In this regard, it is demonstrated that these nanoparticles can not only be used
in diagnostics and as drug delivery agents, but also as active pharmacophores.
Finally, the third part of this dissertation is a report of novel ionic liquid based pH
sensitive colorimetric nanosensors based on phosphonium and fluorescein. The pH dependent
xvi

size changes in the nanodroplets are demonstrated and potential applications in detecting
acidic environment and anticancer activity are investigated.

xvii

CHAPTER 1. INTRODUCTION
1.1. Characteristics of Cancer
Cancer is a pervasive disease that remains a primary health concern in the world today
since its cure has evaded man’s innovativeness and technology for generations. For example, in
the United States, one in every four deaths is the result of cancer.1 Cancer is a group of diseases
characterized by unrestrained growth and spread of abnormal cells. Cancer is a consequence of
multiple abnormalities in the genetic composition of the normal cell.2 These abnormalities lead
to progressive conversion of normal cells to cancer cells, a process known as carcinogenesis.
Cancer cells experience excessive stimulation due to mutations in the deoxyribonucleic acid
(DNA) sequence which leads to increased expression of oncogenes and/or loss of tumor
suppressor genes. This stimulation triggers a state of chaos in the growth of cancer vasculature
(highly disorganized with excessive branching) as cancer cells multiply in the body. In contrast,
normal cells live in nearly complete harmony with their environment. Typically, normal genes
have programmed growth machinery that ensure controlled growth, cell division and
programmed cell death, which maintains a balance in cell numbers as required for a healthy
body. When genetic modifications occur, one or all of these patterns are broken and oncogenes
transform the normal cells to cancer cells.3,4 For example, when programmed cell death
(apoptosis) is suppressed, progressive cell division leads to an abnormal increase in the number
of cells and results in a tumor. Thus, by absence of apoptosis, cancer cells become immortalized
and continue to multiply over and over, resulting in suffocation of the neighboring cells due to
the demand of cancer cells for nutrients and oxygen.
Various types of cancers are defined based on the location or organ in which they
develop in the body. One of the greatest challenges in combating cancer is to mitigate its ability
to migrate to other parts of the body through a process known as metastasis. For example,
1

prostate cancer is known to migrate over time to the brain. If metastasis is not terminated, the
entire body or organs may be quickly invaded with cancer, making it difficult to treat and often
leading to death.2
In general, all types of cancers have certain characteristics or features that are similar as a
result of physiological changes they undergo during carcinogenesis. In 2000, Hanahan and
Weinberg outlined six such characteristics referred to as the “hallmarks of cancer”, and two more
were added in 2011 (Figure 1.1).5,6 These are; 1) self-reliance in growth signals, 2) insensitivity
to anti-growth signals, 3) evasion of apoptosis, 4) infinite replicative ability, 5) initiation of
angiogenesis, 6) invasion and metastasis, 7) reprogramming of energy metabolism, and 8)
evading immune destruction.6

Figure 1.1.The hallmarks of cancer. (Adapted from reference 5 and 6).
The first alteration in cell physiology comprises the production of growth signals by
cancer cells to eliminate dependence on stimulus from normal tissue growth microenvironment.
To achieve this autonomy, tumor cells apply molecular strategies that alter the extracellular
growth signals, cell surface growth receptors, and signal transduction.5 The second physiological
change involves avoidance of anti-proliferative signals by evading cytostatic antigrowth signals.
This enables the cancer cells to multiply rapidly without end.7 Thirdly, cancer cells develop
apoptotic resistance via activation of oncogenes and inactivation of the p53 protein. The p53
2

protein is a product of p53 tumor suppressor gene which regulates apoptosis. As a result of
inactivation of p53, cancer cells fail to die and hence become immortal. The fourth physiological
change leads to a crisis that makes cancer cells not only immortal, but also allows them to escape
the natural deterioration that aging brings. Cancer cells accomplish this by disabling pRb and
p53 tumor suppressor proteins, hence avoiding senescence.8,9 The fifth physiological change
encompasses initiation of angiogenesis by cancer cells. This is the stage where cancer cells
develop new blood vessels. These new vessels are especially useful in supplying nutrients and
oxygen to cancerous tissue. As a result, cancer cells avoid starvation that would otherwise ensue
because of the skyrocketing number of cells needing respiration and nutrients.10 The sixth
physiological change of cancer cells consists of their invasion and metastatic ability. This is
facilitated by cell adhesion molecules that activate communication between cells and integrins
that associate cells to extracellular environment substrates. Metastasis is made possible by
transport of tumor cells via the newly formed blood vessels and lymph circulation.11 The
seventh hallmark involves reprogramming of energy metabolism to generate enough energy to
fuel the increased cell growth and division. Cancer cells accomplish this by utilizing both aerobic
and anaerobic glycolysis as compared to normal cells, which are limited to processing glucose
via glycolysis under aerobic conditions.12 The final hallmark ensures evasion of immune
destruction. Proponents of this hallmark propose that human cells and tissue are under a constant
surveillance from the immune system which destroys any detected cancer cells promptly.
Accordingly, solid tumors that eventually survive are those that have managed to evade
recognition by the immune system or limit immunological killing. Collectively, these factors
lead to autonomous functioning of cancer cells and hence the loss of contact/communication
with normal cells due to created gap junctions.6
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Research geared toward treatment of cancer seeks to inhibit one or a combination of these
hallmarks of cancer. The chemotherapeutic compounds outlined in this dissertation induce
apoptosis and stop uncontrolled proliferation of cancer cells in vitro.13-15
1.1.1. Causes of Cancer
Cancer is caused by internal and external factors. Internal factors are those that are within
the individual. External factors are derived from an individual’s interaction with the surrounding
environment.2 Internal factors include inherited mutations, immune conditions, hormones, and
mutations that occur from metabolism. Internal factors are more difficult to control. However,
prior knowledge of family history coupled with early diagnosis may be useful in combating the
type of cancer to which these factors may lead.16,17 External factors include tobacco, infectious
organisms, radiation, and chemicals. Cancer caused by external factors may easily be prevented
by minimizing exposure to, or avoiding, aforementioned factors.17 The unfortunate reality is that
more than ten years may elapse after exposure to external factors before cancer is detected. It is
also important to note that these causal factors may act together or in sequence to initiate cancer.2
1.1.2. Treatment
There is currently no cure for cancer. However, four methods are currently being
employed to treat cancer: surgery, radiation, immunotherapy, and chemotherapy.1 All four may
be used concurrently or independently depending on the progression of the disease and the
benefits to the patient. Surgery involves the removal of cancerous cells. However, re-infection
may occur due to the possibility of residual cancer cells after surgery.18 To increase success rate
of surgery, researchers are currently exploring ways of coupling surgery with fluorescence,
whereby fluorescent labelled selective compounds are used to light up cancer cells in order to
guide the surgeons in removal of affected cells.19,20 For instance, folate conjugated fluorescent
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labels were used recently during surgeries of ten women with ovarian cancer. The surgeons
involved reported a significantly increased number of tumor deposits detected by fluorescence as
compared to conventionally visualized (Figure 1.2).21 Fluorescent chemotherapeutic agents, such
as the ones reported in this dissertation, may offer the advantage of not only lighting up
cancerous cells for effective surgery, but also killing any residual cancer cells after surgery.13

Figure 1.2. Quantification of tumor deposits ex vivo a) color image b) corresponding tumorspecific fluorescence image of a representative area in the abdominal cavity, and c) scoring
based on three different color images (median 7, range 4–22) and their corresponding
fluorescence images (FLI) (median 34, range 8–81);P < 0.001 by five independent surgeons.
(Reproduced from reference 20 with permission from Nature Publishing Group).
The second most common method used to treat cancer is known as radiotherapy or
radiation oncology. It involves use of high energy x-rays to kill or slow cancer cells from
proliferating. Radiotherapy may be used as a palliative or therapeutic treatment. 22 When used for
palliative treatment, the goal is for local disease control or symptomatic relief in cases where a
cure is not possible. The success of radiotherapy depends on the radiosensitivity of the particular
cancer as well as the size of the tumor. Smaller tumors that are more radiosensitive require a
lower radiation dose to kill the cells. Unfortunately, most epithelial cells are poorly
radiosensitive and therefore the use of radiation therapy must be weighed against the benefits and
side effects of using high radiation. In addition, the right dose of radiation is important, since an
under dose increases the risk of recurrence while an overdose leads to toxicity. Furthermore, care
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must be taken to prevent accidental exposure to normal cells and the personnel operating the
equipment to radiation.22,23
Thirdly, drugs that stimulate the immune system to reject or kill tumor cells have been
exploited. This is referred to as immunotherapy.
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Although the tumor microenvironment is

predominantly immunosuppressive,24,25 T-cell and antibody responses against antigens
associated with tumors can be induced in cancer patients.26-28 This introduces antitumor
immunity that may result in spontaneous tumor regression or control of tumor cell proliferation.
Immunotherapy has been demonstrated in patients with melanoma26 and paraneoplastic
neurological disorders.29
The fourth most popular method for treatment of cancer is chemotherapy. In this method,
chemotherapeutic drugs are used to treat, slow, or halt the proliferation of cancer cells. 30,31 Drug
resistance and toxicity of the developed drugs towards normal cells within the proximity of the
tumor, are two major challenges of chemotherapy. In addition, systemic toxicity whereby the
drug targets other fast multiplying cells such as those lining the bone marrow or those
responsible for hair growth is another limitation of chemotherapy. The latter is responsible for
hair loss among cancer patients on chemotherapy. In a quest to address off target toxicity,
scientists are exploring ways of functionalizing current drugs with targeting agents to ensure they
are delivered selectively to cancer cells.32 Design and development of drugs that are selective to
cancer cells rather than rapid cell division is highly sought to minimize systemic toxicity.
Development of nanoparticles for drug delivery and/or as cancer therapeutics is an
emerging area to overcome drug resistance, improve selectivity, and reduce toxicity of
chemotherapeutics. This is driven by research that indicates that nanoparticles can achieve
improved intracellular concentration, while achieving minimal toxicity in normal cells. 32-34 Thus,
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exploitation of nanoparticles to deliver anticancer agents is an area that is growing rapidly. Drugs
that can be easily modified to evade recognition by proteins responsible for drug resistance in
cancer cells would be ideal candidates. A class of compounds known for ease of tunability
should therefore be a natural group to turn to. Ionic liquids (ILs) and group of uniform materials
based on organic salts (GUMBOS) meet this criteria because they are easy to synthesize and
amenable to tunability. Furthermore, since these compounds are composed entirely of ions, they
may be synthesized from cationic or anionic compounds with inherent chemotherapeutic
properties.35-37 By varying the counterions, an array of compounds with varying anticancer
properties and selectivity towards cancer cells can and has been synthesized.13
My dissertation research focusses on synthesis of ILs and GUMBOS, synthesized from
cationic compounds known to have anticancer properties for use in cancer therapeutics and other
biomedical applications. Nanoparticles (nanoGUMBOS) were derived from the hydrophobic
GUMBOS of this series to achieve selectivity towards various cancer cell lines.13 The cationic
compounds selected for this work are highly fluorescent. Consequently, the nanoGUMBOS
derived thereof are fluorescent and hence may have potential applications in cancer imaging in
addition to their therapeutic value.13,15
1.2. Ionic Liquids
Ionic liquids (ILs) are a class of organic salts with melting points below 100 °C. 38 The
cation and anion pair may be composed purely of organic ions or a combination of organic and
inorganic ions. In most cases, the cation is an organic compound of low symmetry with
positively charged nitrogen or phosphorous.39 Commonly used cations are derived from
ammonium, imidazolium, phosphonium, sulfonium, picolinium, thiazolium, pyridinium, and
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ammonium, among others. Examples of popular anions are hexafluorophosphate, tetraphenyl
borate, and trifluoroborate.
There are two broad categories of ILs: room temperature ILs (RTILs) that melt below 25
°C, and frozen ILs (FILs) which are typically solids at room temperature (25 °C) but melt below
100 °C. It is worth noting that the choice of the upper limit temperature, 100 °C, is arbitrary and
serves the purpose of distinguishing IL salts from inorganic salts which have high melting points.
Low melting points for ILs are a result of symmetric packing of the cations and anions that
constitute ILs. The role played by symmetry in dictating the melting points of ILs is well
explained by Seddon et al. who demonstrated that replacing inorganic cations such as sodium
with unsymmetrical organic cations such as 1-ethyl-3-methylimidazolium significantly lowers
the melting point of the resulting ILs.40
Ionic liquids were first attributed to a report by Paul Walden in 1914 when he synthesized
ethyl ammonium nitrate which has a melting point of 12 °C.41 However, there are reports
indicating that researchers started working with ILs prior to 1914.38 Two decades later, the first
patent on ILs emerged, which was geared towards application of ILs in cellulose dissolution.42 In
1948, a series of chloroaluminate ILs were used for electroplating.43 What followed was a series
of works in which ILs were investigated for use in the fields of electrochemistry, organic
chemistry and catalysis in the mid-1970s and early 1980s.44-48 Investigations involving the
application of ILs in electrochemistry continued into the 1990s with synthesis of more versatile
ILs. Perhaps the most significant advancement was the discovery that a variety of different
anions or cations could be paired to yield ILs. Consequently, the number of ILs synthesized grew
exponentially with significant research being devoted to their physical and chemical properties in
the 1980s through 2000s.49-51 Currently, it is estimated that the theoretical number of possible ILs
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that can be achieved via combination of a broad variety of cations and anions is at least a million
for binary ILs, and close to 1018 for ternary ILs.52 In the last two decades, ILs chemistry has
blossomed, with applications expanding beyond electrochemistry, organic chemistry, and
catalysis to other fields such as separation science, engineering, sensing, biological sciences, and
drug discovery, among others.15,53-56 This dissertation will focus on biomedical and sensing
applications.
1.2.2. Synthesis of Ionic Liquids
One aspect that makes it easy to conduct studies on ILs is the simplicity with which they
can be synthesized. There are several approaches employed in synthesis of ILs. A metathesis or
ion-exchange reaction is a common method for synthesis of water immiscible ILs.57 An example
is the synthesis of 1-butyl-3-methylimidazolium hexafluorophosphate from 1-butyl-3methylimidazolium chloride and sodium hexafluorophosphate. The reaction is typically
performed in a biphasic medium such as dichloromethane (DCM)/water. The IL is extracted in
organic phase while the byproduct is generally soluble in water. Several washes with water
affords the IL free from the byproduct.57 A general scheme of such a reaction is shown in Figure
1.3.

Figure 1.3. Synthesis of 1- alkyl-3-methylimidazolium hexafluorophosphate.
For water miscible ILs, this approach cannot be used since both the product and
byproduct are soluble in water. Thus, they may be synthesized by reaction of a silver salt of the
desired anion (if available) with the desired cation. In this case, the resulting silver salt byproduct
is insoluble in water and can be removed easily. Another route is to conduct the experiment in an
organic solvent. The byproduct should be insoluble in the organic solvent e.g. NaCl in DCM. In
9

such a case, both starting materials are not completely soluble in the organic solvent, and so the
reaction is carried out as a suspension for a longer period of time. The suspension is then filtered.
A good example is the synthesis of 1-alkyl-3-methylimidazole with metal salt. This reaction can
be performed in a DCM and the suspension filtered. However, the resulting halide may be
slightly soluble in the IL/ DCM mixture and hence several washes of the organic layer with water
would be necessary to completely eliminate the byproduct. Another method that has been
employed is the acid-base reaction. Indeed, this was the method used when ethyl ammonium
nitrate, the first reported ionic liquid, was synthesized (Figure 1.4).41 This reaction is performed
by reacting ethylamine with nitric acid in an aqueous environment at 4 °C. Upon completion of
the reaction, water is removed by lyophilization.

Figure 1.4. Synthesis of ethyl ammonium nitrate.
Direct combination of a halide salt and a metal halide is another method that has been
used recently, particularly in the synthesis of magnetic ionic liquids such as [bmim] [FeCl 4]. In
such a method, there are no byproducts formed. An equimolar amount of [bmim][Cl] and FeCl 3
are mixed in a dry box with N2 to yield [bmim][FeCl4] (Figure 1.5) which is a brown liquid.
Alternatively, FeCl3.6H2O may be used in place of FeCl3. This leads to formation of two layers,
water and the IL.58

Figure 1.5. Synthesis of 1-butyl-3-methylimidazolium tetrachloroferrate
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1.2.3. Physical and Chemical Properties of ILs
Physical and chemical properties of ILs can be tuned by changing the structure of the
cation or anion. Alternatively, this may be achieved by varying the counterions without any
modification of the chemical structure of the IL. Interest in ILs is driven by the uniqueness of
this class of compounds, notably low vapor pressure, non-volatility, recyclability, wide liquidus
range and ionic conductivity. Wide liquidus range is a result of ILs high thermal stability and
non-volatility. Liquidus range is the temperature between the freezing point and boiling point of
a liquid. Consequently, by having a wide liquidus range ILs are non-volatile organic solvents and
therefore referred to as green solvents.38 Their non-volatility means that they may not lead to
environmental pollution. This was, however, confused to imply that ILs are intrinsically
nontoxic, which is far from the truth.52 Indeed, toxicity data on ILs is now increasingly
available.59 Low vapor pressure of ILs is due to strong interactions between the ions. Good
conductivity of ILs arises from the fact that they are composed entirely of ions which have fairly
high mobility in liquid state or in aqueous media.60
Traditional ILs are polar in nature and therefore are miscible with polar solvents such as
ethanol, acetone and methylene chloride but immiscible with non-polar ones. Polarity and water
solubility of ILs is largely dictated by the type of cation and anion pair.61 In general, if cations
are paired with anions from halides and metal containing complexes, they tend to be highly
soluble in water. On the contrary, bis(trifluoromethanesulfonylimide), tetraphenylborate, and
tetrafluorophosphate anions lead to poor water solubility of resulting ILs.61 Similarly, different
substituents attached to the cation or anion impact polarity and water solubility of ILs.62
The melting points of ILs are also dependent on the structure as well as substituents on
the respective ions. Van der Waals forces are increased with longer alkyl chain substituents. On
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the other hand, this leads to reduced lattice energy and hence a decrease in melting points.
Likewise, larger anions containing delocalized charges tend to result in lower melting ILs.63
Another reason that contributes to ILs displaying lower melting points in comparison to
inorganic salts is the size and asymmetry of the component ions which result in poor crystal
packing (Figure 1.6).64

Figure 1.6. Illustration of frustrated packing in ILs due to asymmetry of component ions.
1.3. From Ionic Liquids to Group of Uniform Materials Based on Organic Salts
Perhaps the greatest driving force for research involving ILs is the fact that ILs are
tunable via simple variations in the anion/cation or by modification of the cationic or anionic
moiety of the IL. Almost every chemical and/or physical property of ILs can be modified by
simply changing the anion or cation. For instance, variable solubilities, melting points and other
physicochemical properties discussed earlier are largely accomplished via introduction of an
alkyl chain length on the cation. Subsequent increase in the size of this alkyl chain leads to
variations in hydrophobicity.65
In 2007, The Warner research group reported a new class of organic salts with similar
properties as ILs, and defined them as Group of Uniform Materials Based on Organic Salts
(GUMBOS). These materials are solids at room temperature with melting points between 25 °C
and 250 °C. Thus, by definition, there is an overlap between ILs and GUMBOS, particularly
12

FILs. However, while most ILs require modification for task specificity (hence the advent of task
specific ILs), most GUMBOS are inherently task specific as they are drawn from non-traditional
cations and anions selected based on the desired application or property of the cation/anion. For
example, cationic dyes known to have biological applications such as rhodamine, ethidium, and
fluorescein have been employed in the synthesis of GUMBOS. It is worth noting that GUMBOS
have similar physical and chemical properties as ILs. Like ILs they are amenable to tunability
and are synthesized using similar methods. Recently, anion variations on GUMBOS was
demonstrated to lead to variations in physicochemical properties as well as anticancer
properties.13 In addition, magnetic66 GUMBOS have been synthesized via use of magnetic
counterion while GUMBOS with antibacterial properties have been made from well-known
antibiotics starting materials.67 In the same breath, multifunctional ILs/GUMBOS can be
synthesized by carefully selecting cations and anions with desired properties. For instance, the
anion may possess magnetism while the cation possesses anticancer and fluorescent properties.14
Probably the greatest contribution of GUMBOS is the meaning it has brought to FILs. In
the past, considerable efforts have been made to lower the melting points of FILs because the
most important application was use as green solvents. Concerted efforts to replace volatile
organic solvents drove the notion that solid ILs were useless and needed modifications to depress
the melting points to room temperature range. The development of GUMBOS and applications in
many varied fields has revolutionized ionic liquid chemistry. Currently, ILs and GUMBOS are
being investigated in the Warner research group for biomedical applications,13,67 sensing
applications,15,68 and solar cells,69 among others. This dissertation is devoted to discussing
biomedical and sensing applications.
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1.3.1. Nanoparticles Derived from ILs and GUMBOS
Nanotechnology is becoming a part of every aspect of life. Nanoparticles are defined as
particles with sizes below 100 nm and often display unique intrinsic properties such as changes
in morphology, electronic and atomic structure, typically leading to increased surface reactivity
compared to bulk samples.70 NanoGUMBOS are nanomaterials synthesized from GUMBOS.
Nanoparticles have found applications in many industries, including the manufacture of
electronics, automobiles, paints, coatings, appliances, cosmetics and fabrics. Most recently,
nanoparticles are on the cutting edge of biomedical research, and are being explored as
therapeutics, drug delivery agents, cellular imaging, and biological sensors among other
applications.71-76 This is driven by the many abilities nanomaterials possess in comparison to the
bulk form of the compounds used to synthesize them. Use of ILs as solvents or templates in the
synthesis of nanomaterials has gained popularity in the recent past. This is due to ILs ability to
solubilize most compounds as well as their low vapor pressure that enables reactions at elevated
temperatures in comparison to traditional organic solvents. In addition, ILs are capable of
undergoing hydrogen bonding, which allows for ‘self-organization’ and ‘molecular
recognition’.77 More recently, nanoparticles derived from FILs and GUMBOS have been
synthesized. This allows the advantages of ILs and GUMBOS to be translated and possibly
enhanced at nanoscale.78-80 The applications outlined herein exploits the advantages associated
with tunability of ILs and GUMBOS, as well as valuable properties associated with
nanoparticles.13,15
1.3.2. Synthesis of NanoGUMBOS by Reprecipitation Method
Generally, there are many methods for synthesis of nanoGUMBOS and other
nanoparticles. These include aerosol preparation, sol-gel process, micro emulsion templates and
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reprecipitation methods, and many others are being explored and developed. In this dissertation
however, nanoGUMBOS were prepared by additive free reprecipitation method by dispersing
hydrophobic GUMBOS solution in water under sonication.76 Reprecipitation method is preferred
for biological applications because resulting nanoparticles are free from impurities associated
with template assisted methods. Drawbacks of reprecipitation method are the requirement that
the starting materials be hydrophobic and the lack of size control of the resulting nanoparticles.
For the reprecipitation method used in this study, the target compound was dissolved in a
suitable organic solvent to make 1 mM solution. A small volume of this solution was then
injected rapidly into a poor solvent such as water (or cell media) under sonication at room
temperature. Finally, the resulting nanoparticles dispersion was left to age in the dark for 1 h
before characterization or further use. An example of this method is depicted in Figure 1.7.

Figure 1.7. Reprecipitation process of nanoGUMBOS fabrication showing (A) 1 mM stock
solution of GUMBOS solution in ethanol, (B) injection of 100 μL of the GUMBOS solution into
5 mL of deionized water while sonicating the mixture at room temperature, and (C)
reprecipitation of GUMBOS to afford nanoGUMBOS dispersed in water.
Hydrocarbon solvents like hexane, heptane, and iso-octane may be used in place of water for
nanoparticle synthesis of hydrophilic compounds. However, the target compound should be
soluble in corresponding hydrocarbon miscible solvents such as acetone. Factors such as
concentration of the injected solution, temperature of the poor solvent, and aging time may
affect the size, shape and spectral properties of nanoparticles fabricated via this method.81-83
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1.3.3. Active Pharmaceutical Ingredients Based on Ionic liquids and GUMBOS
The search for more versatile ILs has led to the development and application of three
generations of ILs. The ions that make up each of these generations of ILs have also been
employed in the synthesis of GUMBOS. Thus, it is reasonable to refer to the generations as
being of ILs and GUMBOS. Figure 1.8 depicts a number of the ions involved in each of the
generations.

Figure 1.8. Examples of ions employed in synthesis of a) first generation b) second generation
and c) third generation ILs and GUMBOS
The first generation was geared towards understanding the intrinsic physical and
chemical properties of ILs. Some of the properties that were investigated in detail included
viscosity, density, solubility, chemical stability, conductivity, and thermal stability. The second
generation of ILs focused on the tuning of the physical and chemical properties to yield ‘taskspecific’ ILs as well as environmentally friendly (green) solvents. The third and most current
generation of ILs encompasses active pharmaceutical ingredients (API). The goal of the third
generation ILs is to generate ILs with biological activity geared towards overcoming present
hurdles associated with APIs.84,85 Therefore, the cations and anions were judiciously chosen to
possess properties useful for biological applications. For instance, while the first generations ILs
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were mostly non-luminescent, this property was introduced in the third generation ILs by
selecting cations from fluorescent compounds. It is estimated that half of all drugs are
administered as salts. Thus, salt formation of drug targets is an important pre-design step. This is
because salts in APIs are expected to improve solubility in water, safety, industrial processing as
well as biological properties. Most importantly, these properties can be enhanced by variation of
the counterion of the active component.13,85
A more current concept where therapeutic ILs and GUMBOS are being developed, as
opposed to being simply ingredients, has the potential to revolutionize the pharmaceutical
industry. Indeed, reports have emerged exploring this concept on ILs and GUMBOS.13,67,86
Theoretically, it is possible to form a combination of two or more drugs with opposite ions as
long as the resulting cation and anion pair is stable. Newly formed IL/GUMBOS therapeutic
consist of an API, which may be either a cation or an anion, and a counterion selected from a
non-toxic, pharmaceutically acceptable compound. The ILs/GUMBOS introduce unique
properties not found in ordinary crystalline salt forms. These properties may include improved
solubilization as well as uptake in diseased tissue. Most importantly, these properties may be
tuned to arrive at an ideal drug whose efficacy and uptake is highly improved. For example, an
active compound with tendencies to undergo polymorphism may be paired with a counterion
with known tendencies to produce low melting ILs/GUMBOS to overcome polymorphism.
Similarly, an active compound with negative side effects may be paired with a counterion that
neutralizes the side effects. Another interesting example involves pairing two active ions for dual
treatment with synergistic rather than additive results. In this regard, anesthetic lidocaine was
converted to lidocainium docusate ionic liquid. The latter was found to have enhanced and
prolonged effect on rats as compared to traditionally used solid hydrochloride salt. 87 While most
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of these examples are of RTILs,88 FILs and GUMBOS are increasingly emerging to address
problems associated with drugs that may not be converted to liquids. In this regard, GUMBOS
have widened the tunable range in comparison to ILs. In one report, the Warner research group
has demonstrated the usefulness of GUMBOS in antibacterial therapy,67 while several reports
from the same group document applications of GUMBOS and nanoGUMBOS towards cancer
therapy and bioimaging.13,14,78
1.3.4. Ionic Liquids and GUMBOS with Anticancer Properties
Limited reports exist on use of ILs as anticancer agents.89,90 Recently, three classes of ILs
(imidazolium, phosphonium and ammonium) were investigated for anticancer activity and
cytotoxicity towards 60 human cell lines by the National Cancer Institute’s (NCI). Preliminary
structure-activity relationship (SARS) from this data suggested that the length of the alkyl chain
on the cation plays a significant role in the antitumor activity and cytotoxicity of ILs.
Phosphonium-based ILs were found to be more active and less cytotoxic in comparison to the
ammonium and imidazolium-based ILs.91 Substitutions on the N-3 position in the imidazole ring
of the imidazolium ILs played a critical role in antitumor activity and cytotoxicity. It was
observed that ILs with C-12 chain length were effective against all 60 tumor cell lines and
displayed low cytotoxicities. In general, further increase in alkyl chain length was accompanied
with improved antitumor inhibition as well as high cytotoxicity.92 Frozen ILs and GUMBOS
have recently started gaining popularity as anticancer agents, and is the subject of this
dissertation.13,14
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1.4. Analytical Methods Used
1.4.1. Ultraviolet- Visible Spectroscopy
Ultraviolet-Visible Spectroscopy is a characterization technique for analyses of
molecules that absorb light in the ultraviolet and visible region of the electromagnetic spectrum.
Absorbance-based techniques are widely used in clinical experiments to evaluate the viability of
microorganisms because the devices are simple to use and rapid. A UV-vis spectrophotometer
(Figure 1.9) measures the amount of energy that molecules absorb when exposed to light.

Figure 1.9. Schematic diagram of a UV-vis spectrophotometer
The light source (lamp) generates energy which is passed through a monochromator that
selects the desired wavelengths. A beam splitter divides the light into two beams of light through
the sample and reference cells respectively. Light absorbed or transmitted by the sample is
recorded by a detector (photomultiplier tube or diode array). The absorbance or transmittance
may then be plotted against the wavelength to produce a spectrum. The amount of light
absorbed, termed as absorbance (A) is related to the molar absorptivity (Ɛ) and concentration of
the analyte as well as the path length (b) of the cuvette by the Beer- Lambert’s law, symbolized
as A=ƐbC. From this equation, a calibration curve with known concentrations of analytes may be
used to determine an unknown concentration of a sample.93
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A 96- well microplate reader was used to perform absorbance measurements for the
biological assays in this dissertation. In general, UV-vis spectrophotometers and microplate
readers differ mainly in their beam geometry. In conventional spectrophotometers, samples are
read through a cuvette with a horizontal (cross-sectional) light path. In microplate readers, the
light beam is vertical which results in a pathlength that depends on the volume of fluid in each
well.

94

A microplate reader is capable of reading several samples at the same time compared to

one sample at a time for conventional spectrophotometer. Sample holders for microplate readers
are made of optically transparent multiple well plates, the most common being a 96- well plate.94
1.4.2. Mammalian Cell Cytotoxicity
In vitro cytotoxicity assays are important to assess cellular damage that may arise from
exposure of cells to different chemical agents. Cell viability assay is an important tool in drug
discovery because it offers a rapid method to screen potential drugs. The most common of these
assays is based on the absorbance of tetrazolium-converted formazan dyes. This method is
dependent on the sensitivity of an absorbance microplate plate reader, cell types, metabolic
markers, incubation time, and the number of cells. The principle behind tetrazolium-based assays
is founded upon the cellular metabolic activity of live cells. Cellular enzymes in viable cells
reduce tetrazolium dye into formazan while dead cells do not lead to this conversion. As a result,
the absorbance of the formazan is proportional to the amount of viable cells. Typically, cells are
treated with test compounds for 24-72 hours prior to this type of assay. At least 24 h treatment of
the cells is required before cell viability assay is performed to eliminate absorbance that may
result from dying cells and limit the result to cells that survive the treatment.
The first tetrazolium based assay for measuring cell viability was developed by Mosmann
in 1983. In this assay, viable cells reduce the yellow aqueous MTT (3-(4,5-dimethylthiazol-2-yl)-
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2,5-diphenyltetrazolium bromide) solution into a purple formazan solid (Figure 1.10).95 Thus, an
organic solvent must be added to dissolve formazan solid to make absorbance measurements
possible.

Figure 1.10. Conversion of MTT to insoluble formazan by cellular enzymes in viable cells.
Commonly used organic solvents are isopropanol, dimethylsulfoxide, and sodium
dodecyl sulfate/dimethylformamide solutions. This two-step assay produces a homogeneous
purple solution with absorbance maxima at 570nm that is directly proportional to the number of
viable cells.96 In a quest to avoid use of toxic organic solvents, a second tetrazolium, MTS (3(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner
salt) was developed (Figure 1.11).97

Figure 1.11. Conversion of MTS to soluble formazan by cellular enzymes in viable cells.
This differs from MTT assay in that the product is water-soluble, and hence a co-solvent
is not necessary. In addition, it absorbs at 490 nm and has similar benefits as MTT. 98 Thus, in
choosing the best tetrazolium based assay method, one must be aware of the region at which test
compounds absorb. In addition, other factors such as assay length and amount of MTT/MTS to
use per well must be optimized for each cell line to capitalize on the benefits of these assays. In
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this dissertation, MTT assay was preferred for rhodamine based GUMBOS while MTS assay
was used for phosphonium based GUMBOS.
1.4.3. Fluorescence Spectroscopy
Fluorescence is a radiative transition of excited molecules from the first excited singlet
state to ground state. The principle of fluorescence is demonstrated by use of the Jablonski
diagram (Figure 1.12).

Figure 1.12. Perrin- Jablonski diagram
Briefly, molecules are irradiated and upon absorbing light they are promoted to the first
excited singlet electronic state or higher. For fluorophores that are excited to higher electronic
states (>S1), they undergo non-radiative decay via internal conversion (IC) to S1 prior to
fluorescence. A photon that undergoes IC emits less energy than it absorbed leading to a shift in
the emission spectrum to a longer wavelength (lower energy) relative to excitation wavelength.
This change is referred to as Stokes shift. Stokes shift may result from factors such as solvent
effects, energy transfer, and the formation of complexes.94 Excited molecules may also undergo a
less probable radiative decay process known as phosphorescence. Phosphorescence occurs when
an excited photon undergoes intersystem crossing (ISC) to the excited triplet state followed by
radiative transition to the ground state. Phosphorescence is a slower process with an excited state
lifetime between 10-6 and 1 s, compared to fluorescence which is between 1x10-7 to 1x10-9
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seconds. 94 A fluorometer comprises of a light source, excitation and emission monochromators,
and a sample chamber and detector, which may be a photomultiplier tube, photodiode or a CCD
(Figure 1.13).

Figure 1.13. Schematic representation of a fluorometer
The excitation monochromator allows light of selected wavelength, usually between 200
to 900 nm, to illuminate the sample. Emitted light is collected at a right angle to the incident light
and passes through the emission monochromator which eliminates scattered rays prior to
reaching the detector. Common light sources used in fluorescence spectroscopy include lasers,
photodiodes, and lamps. Optically-transparent cuvettes (e.g. quartz, glass, polystyrene) are used
in a conventional fluorometer to maximize on the transmission and collection of excited and
emitted light.
1.4.4. Fluorescence Microscopy
Fluorescence microscopy is a popular technique in biomedical studies.99 In this
dissertation, fluorescence microscopy was utilized in visualizing GUMBOS and nanoGUMBOS
in mammalian cells. The principle is the same as for the conventional fluorometer discussed
earlier with the only fundamental difference being the ability to visualize samples at the
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microscopic level. Hence, cellular compartments can be visualized with the help of fluorescent
probes or cellular markers.100
A fluorescence microscope consists of a xenon- arc or mercury vapor lamp, dichroic
mirror, excitation, and emission filter (Figure 1.14). The dichroic mirror reflects the excitation
light and transmits the emitted light. The excitation filter is used to select light of specific
wavelengths and to ensure that the light incident on a sample is monochromatic. The emission
filter allows light of longer wavelength to pass through to the detector. It is worth noting that all
the filters are interference filters with very specific wavelength selectivity.100

Figure 1.14. Schematic representation of a conventional fluorescence microscope
1.4.5. Confocal Laser Scanning Microscopy
Confocal laser scanning microscopy (CLSM) is a powerful technique for acquiring high
resolution fluorescence images, otherwise challenging for the regular fluorescence microscope. It
achieves this through optical sectioning of the sample.101 A CLSM consists of a laser source,
dichroic mirror, pin-hole, photomultiplier tube (PMT), and a computer (Figure 1.15). Optical
sections of a sample are produced via point by point scanning of the specimen with a laser beam.
A pin-hole or a slit eliminates out-of-focus fluorescence from below and above the focal plane
under investigation.102 The dichroic mirror separates the emitted light from the excitation light
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and passes the emitted light to a pin-hole. The PMT detects the emitted light emerging from the
pin-hole, and the computer processes this signal to produce an image.102

Figure 1.15. Schematic depiction of a confocal laser scanning microscope
Optical paths in a CLSM are designed in such a way that the laser beam focused on a
sample is confocal with the point of light focused at the pinhole in front of the
photodetector.101,103 Therefore, unlike a conventional fluorescence microscope, CLSM ensures
that the only information that reaches the detector emanates from the focal plane of interest. This
techniques has made it possible to image thick specimens with high resolution.104 For example,
with a lens of 1.4 numerical aperture, structures with discrete levels in an intact biological
sample can be imaged to a theoretical lateral resolution of 0.14 μm and a vertical resolution of
0.23 μm.101,104 A series of images from several focal planes can be merged together to
reconstruct a 3-D image, making CLSM a powerful tool for biologists.102 In addition to imaging
thick specimens, CLSM has been successfully employed in imaging mammalian cells and
particularly in visualizing fluorescently labeled subcellular compartments.103
1.4.6. Transmission Electron Microscopy
Transmission electron microscopy (TEM) is a powerful tool for analysis of nanoparticle
size and morphology. The specimen should however be transparent to electrons. A series of
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magnetic lenses are used to focus a beam of electrons which in turn bombard a sample mounted
on a carbon coated copper grid.105 Some of the electrons are transmitted through the sample onto
a detector (fluorescent screen) on the opposite side of the electron beam, while most of the
electron impinges on the sample. The transmitted electrons generate electronic signals that are
utilized to create a TEM image. The transmission electron microscope consists of a vacuum
chamber, the electron gun, condensers and electromagnetic lenses (Figure 1.16).

Figure 1.16. Schematic representation of a transmission electron microscope
The vacuum is necessary to protect electrons from being absorbed by air.105 The electron
gun is the source of electrons and consists of a heated tungsten filament (cathode), a cylinder and
an anode maintained at a high positive potential relative to the cathode in order to accelerate
electrons away from the filament. The condenser focuses the electron beam emerging from the
anode into a narrow intense beam of electrons. An objective lens, intermediate lens and a
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projector lens successively increases magnification of the image. The image may be formed on a
fluorescent screen or on a photographic plate.105
1.4.7. Zeta Potential Analysis
Measurement of zeta potential is used to determine the surface charge of particles in
solution.106 Zeta potential measurements of nanoparticles in this dissertation was performed
using a Malvern Zetasizer Nano ZS instrument equipped with a HeNe laser operating at 632.8
nm and a scattering detector at 173 degrees. Nanoparticles have a surface charge that attracts a
thin layer of ions of opposite charge on its surface. Therefore, as the nanoparticle travels via
diffusion through the solution, the double layer of ions travel with it, creating an electric
potential at the surface of the double layer.107 This potential is referred to as zeta potential and is
used to predict the relative stability of nanoparticles in solution. Generally, nanoparticles with a
zeta potential greater than +25 mV or smaller than -25 mV are said to have a higher degree of
stability.108 Those with zeta potentials between these two values are expected to aggregate or fall
out of solution with time as a result of Van der Waals inter-particle attractions. However, these
generalizations are only true for samples that are highly monodispersed, have a high
concentration enough to scatter 633 nm light, and are suspended in water of high purity free from
any particulates. Unfortunately, this rigorous criterion is rarely met with most samples. For
instance, a highly conductive sample may lead to polarization and degradation of the electrode,
while very dilute samples will not provide enough light scattering events for accurate zeta
potential measurements.108
1.4.8. Superconducting Quantum Interference Device
A superconducting quantum interference device (SQUID) was used to determine the
magnetic properties of the multifunctional materials reported in this dissertation. A
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superconducting quantum interference device is a magnetometer that consists of a semiconductor
loop interrupted with one or more Josephson junctions. It has patterned multilayer structures with
superconducting and insulating thin films.109,110 An interference signal resulting from tunneling
of electron pairs is quantified when an electric current is passed across the Josephson junction
(Figure 1.17). The variation in electrical current is directly proportional to the magnetic
susceptibility of the sample.110

Figure 1.17. Schematic representation of a SQUID
1.5. Scope of the Dissertation
This dissertation is composed of two parts. In the first part, ILs, GUMBOS and
nanoGUMBOS are explored as possible chemotherapeutic agents. The second part outlines the
use of ILs based nanomaterials as a colorimetric pH sensor and use of the pH responsive
nanodroplets as anticancer agents.
In the second chapter, the synthesis and characterization of rhodamine 6G based
GUMBOS and nanoGUMBOS is discussed. The effect of counterion variations on rhodamine
6G is explored, and interesting findings are reported. A close attention is paid on the influence of
variations of hydrophobicity on selectivity of these GUMBOS towards breast cancer cell lines. 13
In the third chapter, the synthesis and characterization of multifunctional organic nanoparticles
derived from phosphonium-dysprosium salts is presented. The effect of the synthesized
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nanoparticles on five mammalian cancer cell lines and one normal cell line is presented and
compared with previously published literature involving the bulk materials. Interesting results in
which the nanoparticles formulations were found to be more effective than their bulk
counterparts is revealed and discussed.14 In the fourth chapter, another group of multifunctional
nanomaterials based on iron (III) phthalocyanine cation and deoxycholate anion is presented.
These materials were designed to possess magnetic properties from iron (III) and near infra-red
fluorescence useful for low energy tissue imaging from the phthalocyanine moiety.
Responsiveness of the nanomaterials to pH is reported. Chapter five outlines the synthesis,
characterization, and application of ionic liquid nanomaterials based on tetraphenyl
phosphonium and fluorescein. The application of these nanomaterials as pH nanosensors is
discussed.15 In addition, the wide applicability of these ILs nanomaterials is demonstrated via
evaluation of their anticancer properties.
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CHAPTER 2. TUNABLE CYTOTOXICITY OF RHODAMINE 6G VIA ANION
VARIATIONS*
2.1. Introduction
There has recently been a tremendous growth in the number of compounds developed as
chemotherapeutic agents for treatment of cancer. However, two major obstacles are relevant for
chemotherapeutic agents: toxicity towards normal cells and drug resistance. Cationic compounds
and multilamellar vesicles with positive charges have been vigorously investigated for this
purpose.1-4 For example, cationic rhodamine dyes have been demonstrated to be good candidates
for this line of research and a number of reports exist dating back to as early as the 1970’s.5-8
Most of these studies suggest that cationic compounds accumulate in the mitochondria of tumor
cells due to the unusually high negative mitochondrial membrane potential of tumor cells as
compared to normal cells. Upon accumulation and subsequent retention, cationic compounds
lead to disruption of adenosine triphosphate (ATP) synthesis in the mitochondria which
eliminates the power source of these cells.

6,7

Other investigations suggest that only the cationic

dyes with delocalized positive charge show mitochondrial selectivity7-9 with little or no focus on
the role played by the counter anion. For example, Lampidis and co-workers have performed
some very thorough and impressive research on the toxicity of cationic compounds.10-13 In one of
these studies, they report the selective toxicity of cationic rhodamine analogues (rhodamine 123
and 6G), tetraphenyl phosphonium (TTP+), and safranin O towards breast cancer cell line
(MCF7) in comparison to the normal monkey kidney cell line (CV-1).6

*Reproduced in part with permission from Magut, P. K. S.; Das, S.; Fernand, V. E.; Losso, J.;
McDonough, K.; Naylor, B. M.; Aggarwal, S.; Warner, I. M., Tunable cytotoxicity of rhodamine
6g via anion variations. Journal of the American Chemical Society 2013, 135, 15873-15879.
Copyright © 2013, American Chemical Society.
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However, later studies with matched pairs of normal and breast cancer cell lines revealed
that rhodamine 123 has no preferential retention or toxicity towards either of these cell lines.
Thus, the selectivity reported earlier was attributed to drug resistance caused by a multi-drug
resistance (mdr-1) gene apparently found in the CV-1 cell line, but absent in normal and breast
cancer cell lines.10 It is with these findings in mind that we chose to investigate the effect of
counter anions on the antitumor activity of rhodamine 6G to examine if such a change may
impart selectivity, particularly towards matched normal and breast cancer cell lines. These anion
variations also led to synthesis of organic nanoparticles from the more hydrophobic compounds
as discussed later.
Our interest in organic nanoparticles is driven by the significant attention this area has
drawn among researchers in the recent past.14-18 In addition, many types of organic nanoparticles
have the advantage of ease of tunability which allows potential applications in varied fields such
as optoelectronics, bioimaging, and optical data storage.17,19-23 The high load of fluorophores in
molecular assemblies within nanoparticles is one property that makes them particularly attractive
for biomedical applications.24 With regard to cancer cells, it has been proposed that nanoparticles
can achieve increased intracellular concentration, while achieving minimal toxicity in normal
cells.25 Consequently, many recent advances in cancer research to address toxicity of
chemotherapeutic agents towards normal cells have led to exploitation of nanoparticles.26
Relative hydrophobicity has been shown to influence drug uptake and subcellular
distribution of chemotherapeutic agents.27 To this end, many approaches to varying the
hydrophobicity of potential anticancer drugs, especially cationic compounds, involve addition of
new groups via covalent bonding or increasing alkyl chain lengths that leads to tedious synthesis
of new organic compounds with a primary focus on the contributions of the cation to their
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anticancer properties.27 In the study outlined in this manuscript, we sought to minimize structural
differences from the cationic precursors by investigating the effect of the anion on the
hydrophobicity and antitumor properties of these compounds in vitro. To achieve this goal, we
have employed a much simpler strategy to developing compounds with varying hydrophobicities
using the concept of variations in hydrophobicity employed for ionic liquids (ILs).28 In this
approach, the cationic dye of choice is held constant while organic counter-anions of varying
sizes and lipophilic properties are coupled via simple ion exchange procedures.20 These
compounds are derived from a new class of compounds referred to as a group of uniform
materials based on organic salts (GUMBOS). GUMBOS are typically solids which possess many
of the attractive properties of ILs.29 Although GUMBOS share similar properties to ILs, these
solids are defined as having melting points ranging from 25 °C to 250 °C, thus broadening the
tunable hydrophobic and melting point ranges for select designer materials applications.
Additionally,

as

hydrophobicity increases,

water

insoluble

nanoparticles

known

as

nanoGUMBOS can be fabricated from GUMBOS.16,20,30 Recently, using a similar concept for
solubility of organic compounds in water, Kasai and co-workers have fabricated nanodrugs with
anticancer properties from camptothecin derivatives that are insoluble in water.14
In this study, we have used the traditionally measured 1-octanol/water partition
coefficients to gauge the relative hydrophobicity of these compounds.31 On the basis of this
measure of hydrophobicity, cell viability results revealed that nanoGUMBOS synthesized from
hydrophobic GUMBOS are non-toxic to normal cells and toxic to cancer cells while rhodamine
6G chloride and the hydrophilic GUMBOS inhibited cell proliferation for both normal and
cancer cells in vitro. The anions in combination with sodium or lithium ions were non-toxic to
both normal and cancer cells. In the studies introduced in this manuscript, we demonstrate that
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both the cation and anion play an active and cooperative role in the observed cytotoxic
properties. To the best of our knowledge, this study is the first of its kind. Furthermore, we
believe that this approach may be a general one and that this discovery may be of great
significance in medicinal chemistry, cancer therapy, and fluorescence bioimaging.
2.2. Materials and Methods
2.2.1. Materials
Human serum and glutaraldehyde were purchased from Sigma Aldrich (St. Louis, MO)
and used as received. Sodium tetraphenyl borate (99.5%), sodium trifluoromethanesulfonate
(98%), sodium L-ascorbate (98%), rhodamine 6G (95%), phosphate buffered saline, methylene
chloride, anhydrous acetonitrile, ethanol (spectroscopic grade), crystal violet, digitonin, carbonyl
cyanide 3-chlorophenylhydrazone (CCCP) and 0.2 μm nylon membrane filters were purchased
from Sigma Aldrich (Milwaukee, WI). Lithium bis (perfluoroethylsulfonyl) imide was donated
by Dr. Gary Baker (Oak Ridge National Laboratory, Oak Ridge, TN). Cell viability MTT (3-[4,
5-Dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide) and Mitochondrial ToxGloTM Assay
kits were purchased from Promega Corporation (Madison, WI). Cell death ELISA assay kit was
purchased from Roche Applied Sciences (Indianapolis, IN). Triply deionized water (18.2
MΩ·cm) from an Elga model PURELAB ultra water filtration system (Lowell, MA) was used
for all preparations of GUMBOS. A BRANSON 3510RDTH model bath ultrasonicator (335 W,
40 kHz frequency) (Branson Ultrasonics Corporation, Danbury, CT) was used at room
temperature for preparation of nanoGUMBOS.
2.2.2. Synthesis and Characterization of Rhodamine 6G-based GUMBOS
The rhodamine 6G-based organic salts (GUMBOS) were prepared using ion exchange
procedures similar to those previously reported in the literature with slight modification.20,28 The
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synthesis of rhodamine tetraphenyl borate ([R6G][TPB]) is herein described as a representative
procedure for the hydrophobic GUMBOS. Thirty (30) mg (0.063 mmol) of [R6G][Cl] and 23.6
mg (0.068 mmol) of sodium tetraphenyl borate ([Na][TPB]) salt were dissolved in a mixture of
methylene chloride (DCM) and water (2:1, v/v) and allowed to stir for 24 h at room temperature
(Scheme 2.1a). Afterwards, the DCM bottom layer was washed several times with water to
remove the sodium chloride by-product, and the product was dried by removal of solvent in
vacuo.

Scheme 2.1. Synthesis of a) hydrophobic and b) hydrophilic R6G-based GUMBOS.

41

Further freeze-drying to remove traces of water afforded 46.1 mg (Table 2.2) of [R6G][TPB]. A
different procedure was employed for synthesis of the hydrophilic GUMBOS, [R6G][Asc] and
[R6G][OTf] since these products are relatively more soluble in water

28

(Scheme 2.1b). The

starting materials, [R6G][Cl] and sodium ascorbate ([Na][Asc]) were stirred in anhydrous
acetonitrile for 72 h. The NaCl byproduct was removed by filtration and [R6G][Asc] or
[R6G][OTf] GUMBOS were obtained by removal of acetonitrile under vacuum. The GUMBOS
obtained were characterized by use of 1H NMR (Bruker Avance 400, CDCl3) and elemental
analysis. For [R6G][BETI] and [R6G][OTf],
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F NMR (Bruker DPX 250, CDCl3) was used to

confirm anion exchange. Melting points of the GUMBOS were determined using a MEL-TEMP
capillary melting point apparatus (Stanford Research Systems, Sunnyvale, CA).
2.2.3. Synthesis of Rhodamine 6G-based NanoGUMBOS
NanoGUMBOS were synthesized by use of a slightly modified, additive free
reprecipitation method.32 Briefly, 1 mL of 1 mM GUMBOS were prepared by dissolving in
DMSO such that the final volume of DMSO was no more than 10% and topped off at the 1 mL
mark using cell media (DMEM containing 10% Fetal bovine serum), followed by sonication for
5 min. A 100 μL aliquot of this solution was re-suspended in 1 mL cell media under sonication
to prepare 100 µM of nanoGUMBOS. These nanoGUMBOS were then left to age in the dark for
1 h. For nanoGUMBOS characterization, a few microliters were dropcast onto a carbon coated
copper grid and left to dry at room temperature. Upon drying, the grids were washed several
times with water to remove the cell media. A similar protocol was used to synthesize
nanoGUMBOS for stability studies with water as the solvent instead of cell media. The average
particle size and size distribution of nanoGUMBOS were determined by use of transmission
electron microscopy (TEM) using an LVEM5 transmission electron microscope (Delong
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America, Montreal, Canada) and dynamic light scattering (DLS). The zeta potentials of
nanoGUMBOS at various pH values were measured by using a Zetasizer Nano ZS (Malvern
Instruments, UK).
2.2.4. Absorption and Fluorescence Spectroscopy
UV-vis spectra were collected using a Shimadzu UV-3101 PC UV-Vis-near-IR scanning
spectrometer (Shimadzu, Columbia, MD). Steady-state fluorescence measurements were
recorded at room temperature by use of a Spex Fluorolog-3 spectrofluorimeter (model FL322TAU3; Jobin Yvon, Edison, NJ) equipped with a 450-W xenon lamp and R928P
photomultiplier tube (PMT) emission detector. A 0.4 cm2 quartz cuvette (Starna Cells) was used
to collect the fluorescence and absorbance relative to an identical cell filled with relevant solvent
as the blank. Both normalized and non-normalized absorption spectra were deconvoluted using
principal component analysis, and fits with lowest χ2 values were accepted.16 A two component
Gaussian fit was used to deconvolute both the normalized and non-normalized absorption
spectra.
2.2.5. Quantum Yields and Lifetime Measurements
Quantum yields (QY) of the GUMBOS were measured relative to [R6G][Cl], QY= 0.90
± 0.02.33 The GUMBOS and solution of [R6G][Cl] in deionized water were optically matched at
the excitation wavelength (530 nm) and the QY calculated with corrections for the absorbance of
all dispersions and solutions. The optical density was set at around 0.1 at 530 nm, and the
integrated intensities of the emission spectra, corrected for differences in index of refraction and
concentration.34 Fluorescence Lifetime measurements were performed at Horiba Scientific
(Edison, NJ) using a time domain mode. A picoseconds pulsed laser source of 495 nm was used
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and emission was collected at 550 nm with a TBX detector. The Time Correlated Single Photon
Counting (TCSPC) mode was used for data acquisition with a resolution of 50 ps per channel.
2.2.6. Photostability Measurements
Photostability fluorescence measurements were collected as follows: the excitation/
emission slit widths were maintained at maximum value (14 nm/ 14 nm) for maximum light
exposure of the samples. Appropriate neutral density filters were used in order to avoid
saturation of the detector. Data were collected over a period of 5000 seconds. All measurements
were performed at room temperature by use of a Spex Fluorolog-3 spectrofluorimeter (model
FL3-22TAU3; Jobin Yvon, Edison, NJ) equipped with a 450-W xenon lamp and R928P PMT
emission detector.
2.2.7. Stability Studies
The stability of the nanoGUMBOS in phosphate buffered saline (PBS) at a pH 7.4 and
ionic strength, I = 0.15 M, and in blood serum (10 % Serum in PBS), was monitored by use of
absorption and fluorescence measurements. In a typical experiment, nanoGUMBOS were freezedried and lyophilized to remove water and then re-suspended in 5 mL PBS. Absorbance and
fluorescence emission measurements of the re-suspended nanoGUMBOS were acquired at
various time intervals. A similar procedure was used for a solution containing 10% blood serum
in PBS.
2.2.8. Determination of Hydrophobicity
1-Octanol/ water partition coefficient was used to gauge relative hydrophobicities of
[R6G] - based GUMBOS. High performance liquid chromatography (HPLC) coupled with a
UV-vis detector was used.35 Separation and quantification of the GUMBOS in 1-octanol was
performed on a Shimadzu HPLC system (Shimadzu, Kyoto, Japan) consisting of an SCL-10A
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system controller, two LC-10AD pumps, a DGU-14A degasser, a SIL-10AD autosampler and an
SPD-10AV UV-vis detector (λ = 530 nm). Separation of the analytes was performed at room
temperature using a Phenomenex Luna C18 column, 100 Å pore size, 4 µm particle sizes, 250 ×
4.6 mm i.d. column containing a guard column (Phenomenex, Torrance, CA, USA). The [R6G]based GUMBOS were eluted isocratically at a flow rate of 0.6 mL/ min using an acetonitrile/
water mobile phase (45/55, v/ v) containing phosphoric acid buffer (pH= 3.0). An injection
volume of 20 µL was employed for this study. The concentration of GUMBOS in water phase
was determined using mass balance. In a typical study, a known amount of [R6G][TPB] was
dissolved in a 1-octanol and water mixture (equal volumes) and shaken for 24 h. The upper 1octanol phase was then analyzed by use of HPLC with UV detection and quantified using an
external calibration method. The equation K (o/w) = [GUMBOS] o, e/ [GUMBOS] w, e was used to
calculate the partition coefficient, where ‘K’, ‘o’, ‘w,’ and ‘e’ represents partition coefficient,
octanol, water, and equilibrium state, respectively. It is worth noting that the 1-octanol used in
the partition experiments was pre-saturated with water overnight before use in order to correct
for mutual solubility of the two solvents.35
2.2.9. Cell Studies
2.2.9.1. Cell Culture
In vitro experiments were performed using normal human breast fibroblast (Hs578Bst,
ATCC no. HTB-125), human breast carcinoma (Hs578T, ATCC HTB-126), hormoneindependent human breast adenocarcinoma (MDA-MB-231, ATCC no. HTB-26), and hormonedependent human breast adenocarcinoma (MCF7, ATCC no. HTB-22) cell lines were obtained
from the American Tissue Culture Collection (ATCC, Manassas, VA). All cell lines were grown
to 90% confluence according to ATCC’s instructions before use in further experiments.
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2.2.9.2.Cell Viability Assay
Cytotoxicities of [R6G]-based GUMBOS and nanoGUMBOS for each cell line was
determined by use of MTT Assay kit(Promega Corporation, Madison, WI, USA) according to
the manufacturer’s instructions. Briefly, in a 96-well plate, 5,000 cells in 0.1 mL culture medium
were seeded to each well. After 24 h, the culture medium was removed and discarded followed
by addition of 0.1 mL culture medium containing 0-100 μM test compounds. Each concentration
was performed in triplicates. Use of cell media and maintaining a sterile environment during the
synthesis of nanoGUMBOS allowed their introduction directly into mammalian cells in vitro
without the need to wash or re-suspend. The cells were then incubated for 48 h at 37 ºC, in 5%
CO2 atmosphere. At the end of the incubation period, the cells were treated with 15 μL MTT and
incubated for 4 h. After four hours, 100 μL stop solution was added per well and incubated
overnight. Afterwards, the plate was shaken for 20 seconds to homogenize and cell viability
determined using a micro plate spectrophotometer (Benchmark plus Bio-Rad Laboratories,
Hercules, CA, USA). Absorbance was read at 570 nm with a reference wavelength of 650 nm.
Cell viability as a percentage was determined by computing the ratio between absorbance of the
treated cells and the absorbance of untreated (control) cells taken as 100%. Data was expressed
as mean ± SD
2.2.9.3. Apoptosis
Apoptotic cell death was determined using a cell death ELISA assay kit (Roche Applied
Sciences, Indianapolis, IN) as per the manufacturer’s instruction. In a typical experiment, 106
cells/ well were incubated with 0-70 µM of the test compound for 48 h to induce apoptosis. The
cells were then lysed to produce nucleosomes and apoptotic cell death detected using a
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microplate spectrophotometer (Benchmark Plus, Bio-Rad Laboratories, Hercules, CA, USA).
Absorbance was read at 405 nm with a reference wavelength of 490 nm.
2.2.9.4. Clonogenic Assay
Clonogenic assay was performed according to a procedure described in literature with
slight modifications.36 Briefly, breast cancer cell line MDA-MB-231 was cultured in triplicate in
6-well plates at a density of 50 cells/ well and allowed to attach for two hours. Cells were
observed under a microscope to confirm attachment and then incubated with the test compound
for 48 h. Control wells contained cells with only cell culture medium. After 48 h, the medium
was changed and the cells were allowed to form colonies over a period of one week. The
colonies were then fixed with glutaraldehyde (6 % v/ v), stained with crystal violet (0.5 % w/ v)
and counted using a stereomicroscope.
2.2.9.5. Microscopy
Approximately 5000 Hs578Bst cells, Hs578T cells and MDA-MB-231 cells were plated
on glass bottom culture dishes (35 mm petri dish, 10mm Micro well; Ashland, MA, USA) for
cell adherence a day before use. After 24 h, cells were incubated with the test compound at a
final concentration of 50 µM at 37 °C and 5% CO2 in a humidified cell culture incubator for 48
h. Cell images were obtained under a light microscope (Nikon Diaphot 300; Hoffman
Modulation Contrast) equipped with camera Nikon D70s at a magnification of 20X. Similarly,
for confocal microscopy, cells were incubated with test compounds at a final concentration of 50
nM for 30 min. Cell images were acquired under an oil immersion objective (x40) with a
confocal laser microscope (Leica TCS SP5 AOBS confocal microscope) equipped with an argonkrypton laser.
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2.2.9.6. Cellular Uptake
Cellular uptake was evaluated using flow cytometry following a protocol reported in
literature,37 with slight modifications. Briefly, 3 x 104 cells per well were seeded in a 24- well
plate and incubated for 24 h. The medium was replaced with medium containing [R6G][BETI]
or [R6G][TPB] at 0-50 µM.

In another set of experiments to investigate the effect of

extracellular pH on uptake of nanoGUMBOS by normal breast cell line, Hs578Bst, media was
adjusted to pH 6.5 and 7.4. After 4 h, cells were washed three times with PBS and harvested by
trypsinization. They were then washed again with centrifugation and resuspended in FACS
buffer (0.3% BSA in PBS). Mean Fluorescence intensities were determined by flow cytometry
(Becton & Dickinson, Mountain View, CA, USA).
2.2.9.7. Determination of Mitochondrial Responses to [R6G][BETI] and [R6G][TPB]
To determine whether these compounds inhibited oxidative phosphorylation, a
Mitochondrial ToxGloTM Assay kit developed by Promega Corporation (Madison, WI) was used.
This experiment was performed following the manufacturer’s protocol with slight modification.
The experiment comprised two parts. In the first part, membrane integrity (MI) was assessed,
while in the second part ATP was measured. Briefly, 10,000 cells/ well were grown using
standard media in a white 96- well plate (costar®) and allowed to adhere. These cells were then
washed in serum-free, galactose-containing medium in order to restrict ATP production to
oxidative phosphorylation. Carbonyl cyanide 3-chlorophenylhydrazone (CCCP) was used as a
positive control mitochondrial toxin and digitonin was used as a positive control toxicity
compound. All test compounds and controls were prepared in serum-free galactose-containing
medium. After washing, cells were incubated with the test compounds and controls for 2 h. At
the end of 2h, 20 µL of a 5x diluted fluorogenic peptide substrate (bis- AAF-R110) was
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introduced to each well and mixed by use of orbital shaking for 1 min at 600 rpm. The sample
was then incubated for 30 min at 37 °C followed by measurement of fluorescence using
excitation at 485 nm and measuring emission at 530 nm. This test was considered valid when the
signal from the cytotoxicity control was at least twofold higher than that of the untreated media
control. To determine the amount of ATP, the sample plate was equilibrated to room temperature
for 5-10 min and 100 μL of prepared ATP detection reagent were added to each well followed by
5 min mixing on an orbital shaker at 600 rpm. Data was expressed as percentage of vehicle
control.
2.2.9.8. Statistics
Statistical analyses were performed using one-way analysis of variance (ANOVA).
Tukey’s studentized range test was performed to ascertain significant differences between
treatments within the 95% confidence interval using SAS 9.2 software (SAS, Cary, NC, USA). P
< 0.05 was considered to indicate statistical significance. Results shown are representative of at
least three experiments and are expressed as mean ± SD.
2.3. Results and Discussion
2.3.1. Synthesis and Characterization of Rhodamine 6G GUMBOS
The elemental analysis (Table 2.1) and 1HNMR of all GUMBOS as well as 19F NMR of
[R6G][BETI] and [R6G][OTf] gave results consistent with expectations.
2.3.2. Physical and Morphological Properties
Rhodamine 6G-based GUMBOS displayed variable physical properties based upon
changes in the anion type and size. It was observed that changing the anion affected the melting
points of the GUMBOS (Table 2.2), as is commonly observed in other low-melting organic salts,
such as ionic liquids, due to attenuation of crystal packing by larger anions in such salts.38,39
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Table 2.1. Elemental analysis of rhodamine 6G-based GUMBOS
GUMBOS
C
N

S

Theory
(%)

Found
(%)

Theory
(%)

Found
(%)

Theory
(%)

Found
(%)

Theory
(%)

Found
(%)

[R6GAsc]

66.04

65.96

6.19

5.98

4.73

4.69

5.41

5.30

[R6G][OTf]

58.78

58.60

5.27

5.20

4.68

4.63

-

-

R6G][BETI] 46.67

47.02

3.91

3.79

5.10

5.14

7.78

7.57

[R6G][TPB] 81.88

81.71

6.74

6.75

3.67

3.69

-

-

Table 2.2. Yields, melting points, logarithm of 1-octanol/water partition coefficients of
rhodamine 6G-based GUMBOS and size of corresponding particles.
MW of
Partition
Particle
Yields
Anion
m.p
GUMBOS
Anion
Coefficients
Size
(%)
Structure
(°C)
(g/mol)
(Log Ko/w)
(nm)
[R6G][Asc]

89

176

138

-0.5

N/A

[R6G][OTf]

94

149

239

0.1

N/A

[R6G][TPB]

96

319

83

0.3

92 ± 17

[R6G][BETI]

96

381

64

1.0

101 ± 21

NanoGUMBOS from rhodamine 6G tetraphenyl borate ([R6G][TPB]) and rhodamine 6G
bis(perfluoroethylsulfonyl) imide ([R6G][BETI]) were primarily spherical or slightly ovate as
characterized by use of transmission electron microscopy (TEM) (Figure 2.1) with an average
size of approximately 100 nm. We note that the polydispersity index obtained for these
nanoGUMBOS by use of dynamic light scattering (DLS) was generally good, usually under 0.2.
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The agglomeration observed in Figure 2.1, a, may have resulted from evaporation of the
dispersant.

Figure 2.1. NanoGUMBOS TEM micrographs of a) [R6G][TPB] size: 92 ± 17 nm and b)
[R6G][BETI] size: 101 ± 21 nm. Scale bars represent 500 nm.
One (1)-octanol/water partition coefficients was determined in order to gauge the relative
hydrophobicities of the synthesized compounds35,40 Trends beginning with least hydrophobic
were rhodamine 6G ascorbate ([R6G][Asc])< rhodamine 6G trifluoromethanesulfonate
([R6G][OTf])< [R6G][TPB]< [R6G][BETI] (Table 2.2). These observed variations in partition
coefficients clearly demonstrate that anions play an important role in determining
hydrophobicities of [R6G]-based organic salts. Dissociation constants of rhodamine 6G-based
GUMBOS were also determined (Table 2.3) and observed trends were very consistent with our
measured octanol/water partition coefficients. Compared to [R6G][Cl], [R6G][BETI] and
[R6G][TPB] show very low dissociation constants,

while [R6G][OTf], [R6G][Asc] show

moderate dissociation constants, which underscores the role played by anions in tuning this
physical property of GUMBOS. [R6G][BETI] has dissociation constants of 1.4 × 10-12 and 7.4 ×
10-12 and [R6G][TPB] has values of 1.37 × 10-11 and 1.52 × 10-11 in pH 6.5 and pH 7.4 buffer
solutions, respectively. The low values of dissociation constants of [R6G][BETI] and
[R6G][TPB] in PBS solutions suggest that these two GUMBOS are very insoluble in PBS
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solution, where they form nanoGUMBOS. This study also demonstrates that pH is an important
factor for evaluating solubility of rhodamine 6G-based GUMBOS. Generally, lower pH values
favor less dissociated GUMBOS.
Table 2.3. Dissociation constants of rhodamine-based GUMBOS in buffer solutions
Compound

pH

Solubility
(g/L)

Solubility
(molL-1)

Dissociation constants
Ks (mol2L-2)

6.5

9.56 × 10-4

1.16 × 10-6

(1.35 ± 0.70) × 10-12

7.4

2.23 × 10-3

2.71 × 10-6

(7.36 ± 0.06) × 10-12

6.5

2.82 × 10-3

3.71 × 10-6

(1.37 ± 0.05) × 10-11

7.4

2.97 × 10-3

3.89 × 10-6

(1.52 ± 0.040) ×10-11

6.5

3.28 × 10-2

5.54 × 10-5

(3.07 ± 0.20) × 10-9

7.4

3.61 × 10-2

6.10 × 10-5

(3.73 ± 0.40) × 10-9

6.5

0.50

8.05 × 10-4

(6.49 ± 0.08) × 10-7

7.4

0.43

6.95 × 10-4

(4.83 ± 0.20) × 10-7

6.5

1.37

2.85 × 10-3

(8.11 ± 0.60) × 10-6

7.4

1.68

3.50 × 10-3

(1.23 ± 0.07) × 10-5

[R6G][BETI]

[R6G][TPB]

[R6G][OTf]

[R6G][Asc]

[R6G][Cl]

2.3.3. Absorption and Fluorescence Studies
Ethanolic solutions of [R6G]-based GUMBOS displayed essentially identical absorption
spectra with values of λmax near 525 nm, which were similar to the precursor, [R6G][Cl] (Figure
2.2, a). Use of these compounds in biological systems requires investigations of their spectral
behavior at physiological pH. In phosphate buffered saline (PBS, pH= 7.4, ionic strength, I= 0.15
M), [R6G][TPB] and [R6G][BETI] nanoGUMBOS exhibited broad absorption spectra with a
shoulder in the red region relative to the peak maxima (Figure 2.2, b).
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Figure 2.2. Absorption spectra of [R6G]-based a) GUMBOS in ethanol b) nanoGUMBOS in
PBS. Inset; deconvoluted absorption spectrum of [R6G][TPB] and [R6G][BETI] nanoGUMBOS
(black line), representing randomly oriented aggregates absorbing at λ= 525 nm (red line) and Jaggregates absorbing at λ= 582 nm (blue line).
The deconvoluted absorption spectra (inset of Figure 2.2, b) of [R6G][TPB] and
[R6G][BETI] nanoGUMBOS reveal that each absorption spectrum can be decomposed into two
major bands attributed to two different types of absorbing species.16 The spectral component
absorbing at ~525 nm is assigned to aggregates within the dye nanoGUMBOS with transition
dipoles that are often randomly oriented in dilute solutions.41 The red-shifted spectral component
is attributed to J-type aggregation in which the transition dipoles are arranged in a staircase
manner.42 Although J-aggregation is expected to lead to narrowing of the spectral line, the
absorption profile for our nanoGUMBOS is relatively broader. This broadening may be
attributed to imperfect J-aggregation, lack of motional narrowing, or the presence of lattice
disorder within nanoGUMBOS.43,44 The more hydrophilic GUMBOS, [R6G][Asc] and
[R6G][OTf], displayed absorbance profiles similar to [R6G][Cl], possibly due to similar
solubility in water. An intense fluorescence emission signal from nanoGUMBOS appears near
550 nm with the fluorescence excitation and emission spectra following the expected mirrorimage rule as a result of Franck Condon factors (Figure 2.3, a).
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Figure 2.3. Fluorescence studies in PBS displaying a) fluorescence excitation and emission
spectra of 4 μM [R6G][TPB] nanoGUMBOS and b) photostability of 0.1 μM [R6G] - based
compounds. Fo and F are fluorescence intensities at t= 0 and at different times respectively.
Maximum slit widths of 14 nm were maintained on both excitation and emission.
We determined the quantum yields of the [R6G]-based GUMBOS via a previously
reported comparative method,45 using [R6G][Cl] as the standard.33 The quantum yields were
determined to be 0.87, 1.01, 0.97 and 1.01 for [R6G][Asc], [R6G][OTf], [R6G][TPB, and
[R6G][BETI] respectively while the [R6G][Cl] standard used was 0.90. In addition, we have
determined the lifetimes of these compounds which were 3.92, 3.92, 3.91 and 3.91 for
[R6G][Asc], [R6G][OTf], [R6G][TPB and [R6G][BETI] respectively. The lifetime of [R6G][Cl]
is 3.94. Evaluation of these results reveals minimal differences in quantum yields and lifetimes
with changes in the anion. This implies that fluorescence properties of these compounds are
strongly influenced by properties of the cationic fluorophore and are minimally affected by the
anions.
This feature allowed the fluorescence properties of the R6G moiety to be essentially
maintained, while tuning other physical properties of GUMBOS. Intrinsic photostability was also
monitored to evaluate the molecular response of the GUMBOS and nanoGUMBOS upon
exposure to light. Evaluation of data from these studies revealed excellent photostability with
[R6G][TPB] being the most photostable. It was observed that signal retention ranged from 62%
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to 90% after 5000 seconds of irradiation (Figure 2.3, b) which suggests relatively long shelf life
if these materials were to be developed as drug or imaging contrast agents.
2.3.4. Stability of Rhodamine 6G-based NanoGUMBOS
Colloidal stabilities of nanoGUMBOS in phosphate buffered saline (PBS, pH= 7.4, ionic
strength, I= 0.15 M), and serum-PBS (10% serum in PBS) were investigated by monitoring
absorbance at λ= 530 nm and emission at λ= 550 nm over a 48 h period. We observed a gradual
decrease in the relative absorbance and emission when nanoGUMBOS were dispersed in PBS
(Figure 2.4).
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Figure 2.4. Stability of nanoGUMBOS in a) PBS b) 10% serum and c) absorbance spectra
corresponding to [R6G][TPB] in PBS showing transition from J-aggregates (λ = 582 nm) to
randomly oriented aggregates (λ = 525 nm).
This decrease in signal is partly attributed to adsorption of nanoGUMBOS on the walls of
the glass vial in which they were prepared.46 Attenuation of intensities may also be a result of
nanoparticle aggregation or reorientation with time. It is interesting to note that we observed an
increase in absorbance (Figure 2.4, a) and fluorescence emission for [R6G][TPB]
nanoGUMBOS in PBS, which is attributed to dye de-aggregation over time. This was confirmed
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by monitoring the absorption spectra as depicted in Figure 2.4, c, where the peak earlier
attributed to J-aggregates (λ= 582 nm) for [R6G][TPB] nanoGUMBOS decreased in absorbance
with time as the one attributed to randomly oriented aggregates (λ = 525nm) increased. This
suggests a gradual shift from the more ordered J-aggregates to randomly oriented aggregates in
PBS. In contrast, when nanoGUMBOS were dispersed in serum-PBS, little or no changes in
absorption intensity (Figure 2.4, b) and fluorescence emission were observed. This is likely due
to prevention of non-specific adsorption to the walls of the glass vials by serum proteins. This
observation is consistent with previous literature where bovine serum albumin was used to
prevent non-specific adsorption of PEGylated gold nanoparticles.46 This study of nanoGUMBOS
in serum-PBS suggests a possible fate of these materials if used in vivo. Thus, their extraordinary
stability enhances their potential for such applications.
2.3.5. Cell Studies
MTT assay was used as the primary method for evaluating cytotoxicities, while
microscopy was used to corroborate these findings. Initial studies were performed using a
suspension of hydrophobic GUMBOS in PBS. After examining these suspensions, we observed
the presence of micro- and nano-particles (Figure 2.5).

Figure 2.5. TEM images of a suspension of a) [R6G] [BETI] and b) [R6G] [TPB] GUMBOS.
This displays micro- and nano-sized particles. Bars represent 2 µm.
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Therefore, further studies were performed by synthesis of nanoGUMBOS with an
average size of approximately 100 nm from hydrophobic [R6G][BETI] and [R6G][TPB]. This
ensured uniformity in the size of the nanoGUMBOS. Various cell lines were treated with varying
concentrations of nanoGUMBOS and it was observed that viability of the normal breast cell line
remained largely unaffected, while breast cancer cell proliferation was inhibited in a
concentration dependent manner (Figure 2.6).

Figure 2.6. Cell viability assay of Hs578Bst, Hs578T and MDA-MB-231 cell lines upon
treatment with a) [R6G][BETI] and b) [R6G][TPB]. * Statistically different from control, P
<0.0001.
The MTT assay results were consistent with light microscopy images acquired after 48h
treatment of the cells with [R6G][BETI] and [R6G][TPB] (Figure 2.7). At the end of 48 h, it was
observed that the normal breast cell line (HS578Bst) appeared attached firmly and healthy. In
contrast, the breast cancer cell lines (Hs578T and MDA-MB-231) appeared smaller, round up
and detached consistent with the morphology observed when adherent cells die. It is also
interesting to note that these compounds were found to be more toxic toward more aggressive
and invasive cancer cell lines than toward less invasive cell lines. For example, the IC50 values
for the more invasive and aggressive MDA-MB-231 were 11.4 µM and 12.2 µM for
[R6G][BETI] and [R6G][TPB] respectively, while it was >100 µM for the non-invasive MCF7
(Table 2.4). In contrast, the hydrophilic [R6G][OTf] and [R6G][Asc] inhibited cell proliferation
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of both normal and breast cancer cell lines. A summary of the IC50 values is displayed in Table
2.4.
b)

a)

c)

Figure 2.7. Light microscopy images of a) normal breast cell line, Hs578Bst and breast cancer
cell lines b) Hs578T and c) MDA-MB-231 after treatment with 50 µM [R6G][TPB] for 48h. Cell
images were obtained using a light microscope equipped with a camera at a magnification of
20X.
Table 2.4 IC50 (μM) of R6G-based compounds towards breast cell lines
Hs578Bst IC50
Hs578T IC50
MDA-MB-231 IC50
Compounds
(μM)
(μM)
(μM)
[R6G][Asc]
10.2
21.0
5.0

MCF7 IC50
(μM)
13.3

[R6G][Cl]

34.6

19.2

5.1

30.7

[R6G][OTf]

40.6

18.6

10.2

14.2

[R6G][TPB]

-

25.6

12.2

>100

R6G][BETI]

-

23.8

11.4

>100

Using control experiments, it was observed that the cation, rhodamine 6G, inhibited cell
proliferation of both normal and breast cancer cell lines in agreement with previous literature,6
while the anions [Li][BETI] and [Na][TPB] were not observed to have a significant effect on any
of the investigated cell lines (Figure 2.8). This definitively demonstrates that the cation and anion
combination plays an active and cooperative role in the observed selective properties,
particularly for hydrophobic compounds.
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Figure 2.8. Cell viability assay of Hs578Bst, Hs578T and MDA-MB-231 cell lines upon
treatment with 0–100 μM of a) [Li][BETI] and b) [Na][TPB] controls. *Statistically different
from control, P < 0.0001 for [Li][BETI] Hs578T. Statistical analysis shows no difference from
control for all the others (P > 0.05).
Apoptosis is characterized by membrane blebbing, condensation of cytoplasm, and the
initiation of an endogenous endonuclease. This nuclease cleaves double-stranded DNA
generating mono- and oligonucleosomes. The result is an enrichment of mono- and
oligonucleosomes in the cytoplasm of the apoptotic cell because DNA degradation occurs
several hours before plasma membrane breakdown. Thus, the enrichment factor for apoptotic
cells would be proportional to the concentration of an apoptosis inducing agent. Apoptosis is
determined using a cell death ELISA kit. Results from our experiments indicate that
[R6G][BETI] and [R6G][TPB] induce apoptosis as the enrichment factor increased with an
increase in concentration of the nanoGUMBOS (Figure 2.9).
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Figure 2.9. Effect of a) [R6G][BETI] and b) [R6G][TPB] on cell death of MDA-MB-231 breast
cancer cells. MCF7 and Hs578T cancer cell lines displayed similar trends. The enrichment factor
is the ratio of the absorbance of the sample (dying/dead cells) and the absorbance of the control
(viable cells). *Statistically different from control, P < 0.0001.
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In addition, clonogenic assay revealed that [R6G][BETI] and [R6G][TPB] prevented
colony formation of cancer cell lines when surviving cells were cultured after treatment with a
low dosage of these two compounds (Figure 2.10). Thus, these compounds may be good
candidates for further investigations as possible chemotherapeutic agents. Uptake of
nanoparticles by individual cells is usually mediated by either non-specific or specific receptor
interactions, commonly via endocytosis. The charge, hydrophobicity, and size of nanoparticles
greatly influence this cellular uptake.47,48 The [R6G][BETI] and [R6G][TPB] nanoparticles
displayed a net negative surface charge as gauged by measurement of their zeta potentials.
a)

b)

Figure 2.10. Clonogenic assay images of MDA-MB-231 breast cancer cells showing a) colonies
formed from control wells and b) zero colonies formed in wells treated with 12.5 µM
[R6G][BETI]. Similar results were obtained for [R6G][TPB].
This charge was pH dependent, becoming more negative at physiological pH and less
negative at acidic pH. Breast cancer cell lines have been found to have acidic extracellular pH (~
6.5)49 in comparison to normal cells (~ 7.4 ).50 From our results, at pH 6.5 the zeta potential of
[R6G][BETI] and [R6G][TPB] were -9.9 ± 0.9 and -8.0 ± 0.9 mV respectively while at pH 7.4
they were -16.2 ± 1.2 and -17. 8 ± 1.5 mV respectively. Since the cell membrane is negatively
charged,27 it is reasonable to expect that at pH 7.4, electrostatic repulsion between the
nanoparticles (with high negative charge at this pH) and the cell membrane may lead to reduced
uptake in normal breast cells. At lower values of pH, however, repulsive forces are reduced since
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nanoGUMBOS possess less net negative surface charge and thus may have greater uptake in
cancer cell lines. This uptake may be further enhanced via hydrophobic interactions with cancer
cell membrane. This conclusion is supported by cellular uptake data in which MDA-MB-231
displayed a higher mean fluorescence intensities, in comparison to Hs578Bst, when the two cell
lines were treated with the same concentrations of [R6G][BETI] and [R6G][TPB]
nanoGUMBOS (Figure 2.11).

Figure 2.11. Mean Fluorescence intensity (M.F.I) of breast cancer cell line, MDA-MB-231
(blue) and normal breast cell line, Hs578Bst (red) treated with a) [R6G][BETI] and b)
[R6G][TPB]. *Statistically different from corresponding concentration in Hs578Bst for the same
compound (P < 0.0001).
Furthermore, the acidity of the extracellular pH value in cancer cells is primarily due to
production of lactic acid, a consequence of increased glycolytic activity. This acidity is
proportional to the number of cells as well as aggressiveness of the cell line.51 For example,
MCF7 which is non-invasive and less aggressive has been shown to acidify its extracellular
environment to a lower extent in comparison to the more invasive and aggressive MDA-MB231.51 This is consistent with our results in which IC50 values for MCF7 were above 100 µM for
the two compounds, while for MDA-MB-231 they were slightly above 10 µM as previously
noted. We investigated this line of thought by conducting uptake experiments in the normal
breast cell line at pH 6.5 for various concentrations of nanoGUMBOS. We observed a significant
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improvement in uptake of at least two-fold (Figure 2.12). However, this improved uptake was
still significantly lower in comparison to uptake in the breast cancer cell lines. This implies that
there are other factors contributing to improved uptake in breast cancer cell lines. Studies to
elucidate these other factors including possible differences in cell membranes of the various cell
lines are ongoing in our laboratory.
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Figure 2.12. Mean Fluorescence intensity (M.F.I) of normal breast cell line, Hs578Bst treated
with a) [R6G][BETI] and b) [R6G][TPB] at a pH of 6.5 (blue) and 7.4 (red).
By use of confocal microscopy, the NanoGUMBOS were determined to primarily
localize in the mitochondria (Figure 2.13). Thus, it is reasonable to expect that cell death could
be a result of inhibition of mitochondrial function since this is the mechanism previously
observed for rhodamine 6G.5,52 This conclusion was examined by use of a Mitochondrial
ToxGloTM Assay (Promega Corporation) kit which predicts potential mitochondrial dysfunction
upon exposure to various drugs. The kit consists of two major components. The first is a
fluorogenic peptide substrate (bis- AAF-R110) which cannot cross membranes of live cells;
hence its fluorescence is proportional to dead cells (cytotoxicity).53
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b

a

Figure 2.13. Confocal microscopy analysis of a) [R6G][BETI] and b) [R6G][TPB] in MDA-MB231. The fluorescent images show the DAPI-labeled nucleus (blue), mitotracker deep red 633labeled mitochondria (red), [R6G][BETI] or [R6G][TPB] (green) and a merged image that shows
the two compounds mainly localize in the mitochondria.
The second component is an ATP detection reagent. This reagent lyses viable cells to
release ATP, and in the process produces a luminescent signal that is proportional to the quantity
of ATP present. Test compounds that inhibit oxidative phosphorylation lead to a decrease in
ATP measured with either no change or discordant changes in cytotoxicity. In contrast,
concordant decreases in ATP and increases in cytotoxicity are indicative of primary necrosis and
hence are non- mitochondrial. Based on our observed results, ATP production was reduced with
discordant changes in cytotoxicity of MDA-MB-231 cells exposed to [R6G][BETI] and
[R6G][TPB] (Figure 2.14), indicating that these two compounds are mitochondrial toxins. Thus,
we conclude that toxicity of these two compounds towards breast cancer cell lines result from
inhibition of oxidative phosphorylation in the mitochondria of cancer cells as previously reported
for rhodamine 6G.5,52 This conclusion is consistent with the counter anion of rhodamine 6G
playing a significant and cooperative role in the selectivity observed in the studies reported in
this manuscript.
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Figure 2.14. Profiles of mitochondrial toxicity of a) [R6G][BETI] and b) [R6G][TPB] using a
Mitochondrial ToxGloTM Assay. MDA-MB-231 cells were plated at 10,000 cells/ well and
treated in serial dilutions of compounds resuspended in glucose free (galactose supplemented)
DMEM media for 2 h. A reduction in ATP with discordant changes in membrane integrity
(cytotoxicity) indicates that the two compounds are mitochondrial toxins.
2.4. Conclusion
In summary, we have synthesized and investigated the hydrophobic, luminescence,
stability, and cellular uptake properties of novel fluorescent GUMBOS. In addition,
nanoGUMBOS with an average size of approximately 100 nm in diameter were fabricated by
use of a simple, rapid, reproducible, and additive-free reprecipitation method. We have
demonstrated tunability of the physicochemical properties of these compounds. Most notably,
this study has demonstrated that both the cation and anion in this class of compounds play an
active and cooperative role in the observed selective anti-tumor cell proliferation potential. This
is a remarkable finding since the effect of cationic compounds on normal and cancer cell lines
has been studied for decades with no similar observations. Achieving selective anti-cancer
activity simply by altering the anion of a known anti-cancer agent such as rhodamine 6G opens
new avenues for research and discovery of inexpensive anti-cancer drugs since the synthetic
routes outlined here for production of GUMBOS and nanoGUMBOS are rather simple. A
particularly interesting aspect of this study is that this may be an approach which is generally
applicable to other cationic compounds whose toxicities have been previously studied in detail.
Finally, the luminescence properties of these compounds may allow the design of probes that
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will help to visualize tumor cells for surgical removal, while at the same time inducing cell death
in residual cancerous tissue.
2.5. References
1.

Kelland, L., The resurgence of platinum-based cancer chemotherapy. Nature Reviews
Cancer 2007, 7, 573-584.

2.

Kawakami, M.; Koya, K.; Ukai, T.; Tatsuta, N.; Ikegawa, A.; Ogawa, K.; Shishido, T.;
Chen, L. B., Structure-activity of novel rhodacyanine dyes as antitumor agents. Journal
of Medicinal Chemistry 1998, 41, 130-142.

3.

Abrams, M. J.; Picker, D. H.; Fackler, P. H.; Lock, C. J. L.; Howardlock, H. E.; Faggiani,
R.; Teicher, B. A.; Richmond, R. C., Synthesis and structure of bis[rhodamine 123]
tetrachloroplatinate dihydrate: the first tetrachloroplatinate(II) salt with anticancer
activity. Inorganic Chemistry 1986, 25, 3980-3983.

4.

Takaha, N.; Nakanishi, H.; Kimura, Y.; Hongo, F.; Kamoi, K.; Kawauchi, A.; Mizuno,
M.; Yoshida, J.; Wakabayashi, T.; Miki, T., Significant induction of apoptosis in renal
cell carcinoma cells transfected with cationic multilamellar liposomes containing the
human interferon-beta gene through activation of the iintracellular type 1 interferon
signal pathway. International Journal of Oncology 2012, 40, 1441-1446.

5.

Gear, A. R. L., Rhodamine 6g - potent inhibitor of mitochondrial oxidativephosphorylation. Journal of Biological Chemistry 1974, 249, 3628-3637.

6.

Lampidis, T. J.; Hasin, Y.; Weiss, M. J.; Chen, L. B., Selective killing of carcinoma-cells
invitro by lipophilic-cationic compounds - a cellular basis. Biomedicine and
Pharmacotherapy 1985, 39, 220-226.

7.

Kurtoglu, M.; Lampidis, T. J., From delocalized lipophilic cations to hypoxia: Blocking
tumor cell mitochondrial function leads to therapeutic gain with glycolytic inhibitors.
Molecular Nutrition & Food Research 2009, 53, 68-75.

8.

Chen, L. B.; Summerhayes, I. C.; Johnson, L. V.; Walsh, M. L.; Bernal, S. D.; Lampidis,
T. J., Probing mitochondria in living cells with rhodamine 123. Cold Spring Harbor
Symposia on Quantitative Biology 1982, 46 Pt 1, 141-155.

9.

Johnson, L. V.; Walsh, M. L.; Chen, L. B., Localization of mitochondria in living cells
with rhodamine-123. Proceedings of the National Academy of Sciences of the United
States of America-Biological Sciences 1980, 77, 990-994.

10.

Broutyboye, D.; Kolonias, D.; Wu, C. J.; Savaraj, N.; Lampidis, T. J., Relationship of
multidrug-resistance to rhodamine-123 selectivity between carcinoma and normal
epithelial-cells - taxol and vinblastine modulate drug efflux. Cancer Research 1995, 55,
1633-1638.

11.

Hu, Y. P.; Moraes, C. T.; Savaraj, N.; Priebe, W.; Lampidis, T. J., Rho(0) tumor cells: A
model for studying whether mitochondria are targets for rhodamine 123, doxorubicin,
and other drugs. Biochemical Pharmacology 2000, 60, 1897-1905.

65

12.

Lampidis, T. J.; Castello, C.; Delgiglio, A.; Pressman, B. C.; Viallet, P.; Trevorrow, K.
W.; Valet, G. K.; Tapiero, H.; Savaraj, N., Relevance of the chemical charge of
rhodamine dyes to multiple-drug resistance. Biochemical Pharmacology 1989, 38, 42674271.

13.

Lampidis, T. J.; Planas, L.; Tapiero, H., Selectivity of agents which modulate
anthracycline and rhodamine resistance. Proceedings of the American Association for
Cancer Research 1986, 27, 397-397.

14.

Kasai, H.; Murakami, T.; Ikuta, Y.; Koseki, Y.; Baba, K.; Oikawa, H.; Nakanishi, H.;
Okada, M.; Shoji, M.; Ueda, M.; Imahori, H.; Hashida, M., Creation of pure nanodrugs
and their anticancer properties. Angewandte Chemie International Edition 2012, 51,
10315-10318.

15.

de Rooy, S. L.; El-Zahab, B.; Li, M.; Das, S.; Broering, E.; Chandler, L.; Warner, I. M.,
Fluorescent one-dimensional nanostructures from a group of uniform materials based on
organic salts. Chemical Communications 2011, 47, 8916-8918.

16.

Das, S.; Bwambok, D.; Ei-Zahab, B.; Monk, J.; de Rooy, S. L.; Challa, S.; Li, M.; Hung,
F. R.; Baker, G. A.; Warner, I. M., Nontemplated approach to tuning the spectral
properties of cyanine-based fluorescent nanoGUMBOS. Langmuir 2010, 26, 1286712876.

17.

Tian, Z.; Wu, W.; Li, A. D. Q., Photoswitchable fluorescent nanoparticles: Preparation,
properties and applications. Chemphyschem 2009, 10, 2577-2591.

18.

Peng, A. D.; Xiao, D. B.; Ma, Y.; Yang, W. S.; Yao, J. N., Tunable emission from doped
1,3,5-triphenyl-2-pyrazoline organic nanoparticles. Advanced Materials 2005, 17, 20702073.

19.

Anthony, J. E., Functionalized acenes and heteroacenes for organic electronics. Chemical
Reviews 2006, 106, 5028-5048.

20.

Bwambok, D. K.; El-Zahab, B.; Challa, S. K.; Li, M.; Chandler, L.; Baker, G. A.;
Warner, I. M., Near-infrared fluorescent nanoGUMBOS for biomedical imaging. ACS
Nano 2009, 3, 3854-3860.

21.

Park, S.; Kwon, J. E.; Kim, S. H.; Seo, J.; Chung, K.; Park, S.-Y.; Jang, D.-J.; Medina, B.
M.; Gierschner, J.; Park, S. Y., A white-light-emitting molecule: Frustrated energy
transfer between constituent emitting centers. Journal of the American Chemical Society
2009, 131, 14043-14049.

22.

Yoon, S.-J.; Chung, J. W.; Gierschner, J.; Kim, K. S.; Choi, M.-G.; Kim, D.; Park, S. Y.,
Multistimuli two-color luminescence switching via different slip-stacking of highly
fluorescent molecular sheets. Journal of the American Chemical Society 2010, 132,
13675-13683.

23.

An, B.-K.; Kwon, S.-K.; Park, S. Y., Photopatterned arrays of fluorescent organic
nanoparticles. Angewandte Chemie International Edition 2007, 46, 1978-1982.

24.

Breton, M.; Prevel, G.; Audibert, J.-F.; Pansu, R.; Tauc, P.; Le Pioufle, B.; Francais, O.;
Fresnais, J.; Berret, J.-F.; Ishow, E., Solvatochromic dissociation of non-covalent

66

fluorescent organic nanoparticles upon cell internalization. Physical Chemistry Chemical
Physics 2011, 13, 13268-13276.
25.

Haley, B.; Frenkel, E., Nanoparticles for drug delivery in cancer treatment. Urologic
Oncology: Seminars and Original Investigations 2008, 26, 57-64.

26.

Cho, K.; Wang, X.; Nie, S.; Chen, Z.; Shin, D. M., Therapeutic nanoparticles for drug
delivery in cancer. Clinical Cancer Research 2008, 14, 1310-1316.

27.

Kandela, I. K.; Lee, W.; Indig, G. L., Effect of the lipophilic/hydrophilic character of
cationic triarylmethane dyes on their selective phototoxicity toward tumor cells.
Biotechnic and Histochemistry 2003, 78, 157-169.

28.

Fraga-Dubreuil, J.; Famelart, M. H.; Bazureau, J. P., Ecofriendly fast synthesis of
hydrophilic poly(ethyleneglycol)-ionic liquid matrices for liquid-phase organic synthesis.
Org. Process Res. Dev. 2002, 6, 374-378.

29.

Akdogan, Y.; Junk, M. J. N.; Hinderberger, D., Effect of ionic liquids on the solution
structure of human serum albumin. Biomacromolecules 2011, 12, 1072-1079.

30.

Tesfai, A.; El-Zahab, B.; Kelley, A. T.; Li, M.; Garno, J. C.; Baker, G. A.; Warner, I. M.,
Magnetic and nonmagnetic nanoparticles from a group of uniform materials based on
organic salts. ACS Nano 2009, 3, 3244-3250.

31.

Biagi, G. L.; Recanatini, M.; Barbaro, A. M.; Borea, P. A., Lipophilicity estimation of
drugs. Process Control and Quality 1997, 10, 129-149.

32.

Kasai, H.; Nalwa, H. S.; Oikawa, H.; Okada, S.; Matsuda, H.; Minami, N.; Kakuta, A.;
Ono, K.; Mukoh, A.; Nakanishi, H., A novel preparation method of organic
microcrystals. Japanese Journal of Applied Physics Part 2 1992, 31, L1132-L1134.

33.

Magde, D.; Wong, R.; Seybold, P. G., Fluorescence quantum yields and their relation to
lifetimes of rhodamine 6g and fluorescein in nine solvents: Improved absolute standards
for quantum yields. Photochemistry and Photobiology 2002, 75, 327-334.

34.

Williams, A. T. R.; Winfield, S. A.; Miller, J. N., Relative fluorescence quantum yields
using a computer- controlled luminiscence spectrometer. Analyst 1983, 108, 1067-1071.

35.

Lee, S. H.; Lee, S. B., Octanol/water partition coefficients of ionic liquids. Journal of
Chemical Technology and Biotechnology 2009, 84, 202-207.

36.

Franken, N. A. P.; Rodermond, H. M.; Stap, J.; Haveman, J.; van Bree, C., Clonogenic
assay of cells in vitro. Nature Protocols 2006, 1, 2315-2319.

37.

Vader, P.; van der Aa, L. J.; Engbersen, J. F. J.; Storm, G.; Schiffelers, R. M., A method
for quantifying cellular uptake of fluorescently labeled sirna. Journal of Controlled
Release 2010, 148, 106-109.

38.

Lopez-Martin, I.; Burello, E.; Davey, P. N.; Seddon, K. R.; Rothenberg, G., Anion and
cation effects on imidazolium salt melting points: A descriptor modelling study.
Chemphyschem 2007, 8, 690-695.

39.

Larsen, A. S.; Holbrey, J. D.; Tham, F. S.; Reed, C. A., Designing ionic liquids:
Imidazolium melts with inert carborane anions. Journal of the American Chemical
Society 2000, 122, 7264-7272.
67

40.

Kamlet, M. J.; Abraham, M. H.; Doherty, R. M.; Taft, R. W., Solubility properties in
polymers and biological media.4. Correlation of octanol water partition- coefficients with
solvatochromic parameters. Journal of the American Chemical Society 1984, 106, 464466.

41.

Kasha, M.; Rawls, H. R.; Ashraf El-Bayoum, M., The exciton model in molecular
spectroscopy. Pure and Applied Chemistry 1965, 11, 371-392.

42.

Kumar, V.; Baker, G. A.; Pandey, S., Ionic liquid-controlled J- versus H-aggregation of
cyanine dyes. Chemical Communications 2011, 47, 4730-4732.

43.

An, B. K.; Kwon, S. K.; Jung, S. D.; Park, S. Y., Enhanced emission and its switching in
fluorescent organic nanoparticles. Journal of the American Chemical Society 2002, 124,
14410-14415.

44.

Jelley, E. E., Spectral absorption and fluorescence of dyes in the molecular state. Nature
1936, 138, 1009-1010.

45.

Williams, A. T. R.; Winfield, S. A.; Miller, J. N., Relative fluorescence quantum yields
using a computer-controlled luminescence spectrometer. Analyst 1983, 108, 1067-1071.

46.

Takae, S.; Akiyama, Y.; Otsuka, H.; Nakamura, T.; Nagasaki, Y.; Kataoka, K., Ligand
density effect on biorecognition by pegylated gold nanoparticles: Regulated interaction of
RCA (120) lectin with lactose installed to the distal end of tethered peg strands on gold
surface. Biomacromolecules 2005, 6, 818-824.

47.

Gratton, S. E. A.; Ropp, P. A.; Pohlhaus, P. D.; Luft, J. C.; Madden, V. J.; Napier, M. E.;
DeSimone, J. M., The effect of particle design on cellular internalization pathways.
Proceedings of the National Academy of Sciences of the United States of America 2008,
105, 11613-11618.

48.

Sahay, G.; Kim, J. O.; Kabanov, A. V.; Bronich, T. K., The exploitation of differential
endocytic pathways in normal and tumor cells in the selective targeting of nanoparticulate
chemotherapeutic agents. Biomaterials 2010, 31, 923-933.

49.

Du, J.-Z.; Du, X.-J.; Mao, C.-Q.; Wang, J., Tailor-made dual ph-sensitive polymerdoxorubicin nanoparticles for efficient anticancer drug delivery. Journal of the American
Chemical Society 2011, 133, 17560-17563.

50.

Zhang, X.; Lin, Y.; Gillies, R. J., Tumor ph and its measurement. Journal of Nuclear
Medicine 2010, 51, 1167-1170.

51.

Montcourrier, P.; Silver, I.; Farnoud, R.; Bird, I.; Rochefort, H., Breast cancer cells have
a high capacity to acidify extracellular milieu by a dual mechanism. Clinical &
Experimental Metastasis 1997, 15, 382-392.

52.

Darzynkiewicz, Z.; Traganos, F.; Staianocoico, L.; Kapuscinski, J.; Melamed, M. R.,
Interactions of rhodamine-123 with living cells studied by flow-cytometry. Cancer
Research 1982, 42, 799-806.

53.

Niles, A. L.; Moravec, R. A.; Hesselberth, P. E.; Scurria, M. A.; Daily, W. J.; Riss, T. L.,
A homogeneous assay to measure live and dead cells in the same sample by detecting
different protease markers. Analytical Biochemistry 2007, 366, 197-206.
68

CHAPTER 3. PHOSPHONIUM-DYSPROSIUM DERIVED NANOPARTICLES WITH
CANCER TARGETING PROPERTIES
3.1. Introduction
Nanoparticles for biomedical applications have recently gained increased attention
among researchers.1-5 This is driven by the various inherent advantages of nanoparticles
including increased length of circulation in blood, improved intracellular penetration, and better
retention and accumulation in tumors due to enhanced permeability and retention effect. 6-8 Much
effort has been directed towards attaching ligands for guiding these nanoparticles toward
diseased organelles. Therefore, functionalized nanoparticles are desirable for targeted drug
delivery. Some functions of nanoparticles currently being explored, whether individually or in
combination, include nanoparticles attached to surface enhanced cell penetrating molecules,
specific organelle targeting molecules, increased stability, response to local stimuli such as pH,
and fluorescence capability to allow intracellular visualization among others.9 Many of these
functions are incorporated into nanocarriers such as liposomes, micelles, nanoemulsions, and
polymeric nanoparticles.10,11 However, development of multifunctional nanocarriers requires
much effort, engineering, and cost in order to incorporate all desired properties. It is worth noting
that each functionality introduced increases complexity, size of the nanoparticle, and cost of
production.9 To overcome these challenges, it is best to incorporate anticipated properties into
small molecules prior to nanoparticle synthesis.8 Hence, it is imperative that compounds
synthesized for such nanoparticles possess the preferred properties. This goal requires a class of
compounds amenable to tunability.
Ionic liquids (ILs), defined as organic salts with melting points below 100 °C, fit this
criteria because they possess tunable properties such as melting points, hydrophobicity,
solubility, and thermal stability among others.12 As a result of tunability, ionic liquids have found
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applications in varied fields such as electrochemistry13, solar cells,14 and solvents in industry,15
and they have very recently been investigated for therapeutic purposes, especially cancer.
Several reports have emerged on toxicity of ILs as well as anticancer properties.16-18 Recently, it
was demonstrated that the toxicity of ILs is controlled by several inherent properties of the IL.
These include the alkyl chain length in the cation, extent and type of functionalization on the
side chain of the cation, chemical nature of the ions, and combined influence of anion and
cation.17 The ionic nature of ionic liquids allows the incorporation of complementary properties
in the cation and anion. Using this concept, we recently synthesized and reported a series of
organic salts that are solids at room temperature with multifunctional properties for biomedical
applications.18,19 These salts are referred to as a group of uniform materials based on organic
salts (GUMBOS). They are similar to ionic liquids in terms of properties and tunability, but
unlike ionic liquids, they are solid phase materials with wider melting point ranges between 25
°C and 250 °C.18 From this definition, it should be obvious that there is an overlap with frozen
ionic liquids, which are defined as having melting points between 25 °C and 100 °C.
In this study, multifunctional compounds were designed for therapeutic purposes from
aryltriphenylphosphonium-dysprosium thiocyanate salts. The properties incorporated include
tumor targeting, magnetism, and luminescence. These compounds were designed to derive
fluorescence and paramagnetism from the dysprosium thiocyanate moiety, and mitochondrial
cancer targeting property from the phosphonium group.19 It is important to note that delocalized
phosphonium cations have been investigated and reported to have anticancer properties by
preferentially accumulating in the mitochondria due to the unusually high mitochondrial
membrane potential.20,21 Upon accumulation, they inhibit oxidative phosphorylation, necessary
for energy production in tumor cells, and thus prevent production of adenosine triphosphate
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required for normal cellular function.22-24 Here, we extend this study to nanoparticles derived
from these compounds and evaluate their efficacy in cancer cell lines in vitro. To achieve this,
we had to ensure that the multifunctional properties are retained in the nanoscale through various
characterization techniques. In this study, we report drastically improved half maximal inhibitory
concentration (IC50) values in comparison to those earlier reported for the bulk material,19
indicating that these phosphonium-dysprosium nanoparticles may be potentially better
chemotherapeutic agents than their respective bulk material.
3.2. Materials and Methods
3.2.1. Materials
Tetraphenylphosphonium bromide (98.0%), benzyltriphenylphosphonium bromide (97.0%),
(4-ethoxybenzyl)triphenyl

phosphonium

bromide

(98.0%),

and

(4-nitrobenzyl)triphenyl

phosphonium bromide (98.0%) were obtained from TCI America (Portland, Oregon, USA).
Potassium thiocyanate, dysprosium (III) oxide, and perchloric acid (70%) were obtained from
Sigma-Aldrich (Sigma-Aldrich, Milwaukee, Wisconsin, USA) and used as purchased.
Anhydrous grade ethanol, methanol, acetonitrile, chloroform, and carbon tetrachloride were
obtained from Sigma Aldrich (Sigma-Aldrich, Milwaukee, WI), and all other high performance
liquid chromatography (HPLC) grade organic solvents such as acetone, hexane, and water were
obtained from J.T. Baker (J. T. Baker, Phillipsburg, NJ). Normal human breast fibroblast cells
(Hs578Bst, ATCC no. HTB-125), human breast carcinoma cells (Hs578T, ATCC no. HTB-126),
hormone-independent human breast carcinoma cells (MDA-MB-231, ATCC no. HTB-26),
human pancreatic carcinoma cells (PANC-1, ATCC no. CRL-1469), and human colorectal
adenocarcinoma cells (HT-29, ATCC no. HTB-38) were obtained from the American Tissue
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Culture Collection (ATCC, Manassas, VA) and grown to 90% confluence according to ATCC
protocol.
3.2.2. Synthesis and Characterization of the Phosphonium-dysprosium Salts
Phosphonium-dysprosium

salts

([Ph4P]5[Dy(SCN)8],

[Ph3PBnOEt]5[Dy(SCN)8],

[Ph3PBnNO2]5[Dy(SCN)8], and [Ph3PBn]5 [Dy(SCN)8]) were synthesized and characterized as
previously described.19 Briefly, the following steps were adopted for synthesis of all the
phosphonium-dysprosium salts: In the first step, the four intermediate compounds ([Ph4P][SCN],
[Ph3PBnOEt][SCN], [Ph3PBnNO2][SCN], and [Ph3PBn][SCN]) were synthesized via a facile
metathesis reaction between the respective phosphonium bromide (1 equiv.) and KSCN (2
equiv.) in acetonitrile at room temperature for 2 days.25,26 Dissolving Dy2O3 in 70% HClO4
aqueous solution afforded Dy(ClO4)3.6H2O, which was lyophilized to remove residual water.25
In the second step, ([Ph4P]5[Dy(SCN)8], [Ph3PBnOEt]5[Dy(SCN)8], [Ph3PBnNO2]5[Dy(SCN)8],
and [Ph3PBn]5[Dy(SCN)8]) products were synthesized according to a previously reported
protocol with slight modifications.25,26 As an example, in a typical reaction, a mixture of
[Ph4P][SCN] (5 equiv.), KSCN (3 equiv.), and Dy(ClO4)3.6H2O (1 equiv.) was stirred at room
temperature overnight in absolute ethanol. The KClO4 byproduct (white suspension) was
removed by filtration, and ethanol evaporated. The residue was re-dissolved in dry
dichloromethane (DCM) and the solution allowed to stand overnight in a refrigerator. Filtration
and evaporation of DCM under vacuum afforded the products which were further dried by
lyophilization. Scheme 3.1 displays the structures and the synthesis procedure outlined here. The
four products were characterized by use of 1H,
elemental analysis.
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Scheme 3.1. Synthesis of phosphonium-dysprosium compounds.
3.2.3. Synthesis and Characterization of Nanoparticles from Phosphonium-dysprosium
Salts
Nanoparticles

derived

from

[Ph4P]5[Dy(SCN)8],

[Ph3PBnOEt]5[Dy(SCN)8],

[Ph3PBnNO2]5[Dy(SCN)8], and [Ph3PBn]5[Dy(SCN)8] were synthesized via previously reported
template free reprecipitation method with slight modifications.18,27,28 The synthesis of
[Ph4P]5[Dy(SCN)8] nanoparticles is described as an example. Briefly, 1mM [Ph4P]5[Dy(SCN)8]
was prepared by dissolving in acetonitrile. A 100 μL aliquot of this solution was rapidly injected
into 5 mL deionized water under sonication for 5 min. The resulting nanoparticles were left to
age in the dark for 1 h followed by freeze drying to remove water. This process was repeated
several times to accumulate enough nanoparticles. Particle sizes and images was determined by
use of transmission electron microscopy (TEM) using an LVEM5 transmission electron
microscope (Delong America, Montreal, Canada). The TEM sample was prepared on a carboncoated copper grid (CF400-Cu, Electron Microscopy Sciences, Hatfield, PA). Zeta potentials
were determined using Zetasizer Nano ZS (Malvern Instruments, UK).
3.2.4. Magnetic Properties
Magnetic properties were determined using a Quantum Design Superconducting
Quantum Interference Device (SQUID) magnetometer (San Diego, CA, USA) at temperatures
between 5 and 300 K at a magnetic field of 10,000 Oe.
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3.2.5. UV-Vis Absorption and Fluorescence Spectroscopy
UV-Vis spectra were collected using a Shimadzu UV-3101 PC UV-Vis-near-IR scanning
spectrophotometer (Shimadzu, Columbia, MD). A 0.4 cm2 quartz cuvette (Starna Cells,
Atascadero, CA) was used to collect absorbance relative to an identical cell filled with the
relevant solvent as the blank. Steady-state fluorescence measurements were recorded at room
temperature by use of a Spex Fluorolog-3 spectrofluorometer (model FL3-22TAU3; Jobin Yvon,
Edison, NJ) equipped with a 450-W xenon lamp and R928P photomultiplier tube (PMT)
emission detector. Fluorescence emission spectra were collected in a 0.4 cm 2 quartz cuvette with
slit widths set for entrance exit bandwidths of 4 nm on both excitation and emission
monochromators.
3.2.6. Cell Studies
In vitro experiments employed normal human breast fibroblast cells (Hs578Bct, ATCC
no. HTB-125), human breast carcinoma cells (Hs578T, ATCC no. HTB-126), hormoneindependent human breast carcinoma cells (MDA-MB-231, ATCC no. HTB-26), human
pancreatic carcinoma cells (PANC-1, ATCC no. CRL-1469), and human colorectal
adenocarcinoma cells (HT-29, ATCC no. HTB-38) obtained from the American Tissue Culture
Collection (ATCC, Manassas, VA). The cells were grown to 90% confluence prior to any
experiments according to ATCC’s protocol. Cytotoxicities of the nanoparticles towards each cell
line were determined by MTS Assay kit (Promega Corporation, Madison, WI, USA) according
to the manufacturer’s protocol. Approximately 5,000 cells in 0.1 mL culture medium were
seeded to each well in a 96-well plate. After 24 h, the culture medium was removed and
discarded, followed by addition of 0.1 mL culture medium containing 0-400 μM of the
nanoparticles. The cells were then incubated for 48 h at 37 ºC in a humidified atmosphere
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containing 5% CO2. At the end of the incubation period, the cells were treated with 20 μL MTS
and incubated for 1 h. Absorbance measurements were recorded at 490 nm using a microplate
spectrophotometer (Benchmark plus Bio-Rad Laboratories, Hercules, CA, USA). Cell viability
as a percentage was determined by computing the ratio between absorbance of the treated cells
and the absorbance of untreated (control) cells taken as 100%. The concentration at which 50%
cell proliferation was inhibited (IC50) was computed using a linear fit equation of the linear part
of the cell viability graphs. If the linear portion of the graph did not include 50% cell viability,
IC50 was assumed to be higher than the minimum concentration for which constant cytotoxicity
was attained irrespective of the increase in concentration. The IC50 values were used to compare
cytotoxicities of the various compounds and their corresponding nanoparticles. All experiments
were performed at least three times and the data was expressed as mean ± SD.
Clonogenic assay was performed according to a procedure described by Franken et al.,
with slight modifications.29 Briefly, MDA-MB-231 was cultured in triplicate in 6-well plates at a
density of 50 cells/ well and allowed to attach for two hours. Cells were then incubated with the
test compound for 48h. Control wells contained cells without treatment. The medium was the
replaced with fresh culture medium. Cells incubated and allowed to form colonies over a period
of one week. Finally, cells were fixed with glutaraldehyde (6% v/v), stained with crystal violet
(0.5 % w/v), and counted using a stereomicroscope.
3.2.7. Statistics
Statistical analysis was performed using one-way analysis of variance (ANOVA).
Tukey’s studentized range test was performed to ascertain the significant difference between
treatments within the 95% confidence interval using SAS 9.2 software (SAS, Cary, NC, USA).
P < 0.05 was considered to indicate statistical significance. All data are expressed as mean ± SD.
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3.3. Results and Discussion
3.3.1. Synthesis and Characterization of the Phosphonium-dysprosium Compounds
Characterization of the phosphonium-dysprosium compounds by of 1H,

13

C, and

31

P

NMR, FT-IR (Figure 3.1-3.4), and C, H, N, S elemental analysis gave results consistent with
expectations as follows:
[Ph4P]5[Dy(SCN)8], pale brown solid. Yield, 76%. Mp: 172-175 0C. 1H NMR (400 MHz,
DMSO-d6), δ (ppm): 7.98 (t, 4H), 7.80 (m, 8H), 7.73 (m, 8H). 13C NMR (100 MHz, DMSO-d6),
δ (ppm): 115.8, 135.1, 135.0, 129.3, 118.6, 117.7.

31

P NMR (101 MHz, DMSO-d6), δ (ppm):

23.0. IR (neat), ν (cm-1): 2910, 2855, 2039, 1435, 1107, 839, 672. Anal. Calcd for
C128H100DyN8P5S8: C, 66.15; H, 4.34; N, 4.82; S, 11.04. Found: C, 66.22; H, 4.35; N, 4.78; S,
10.98. In the FT-IR spectra below, the peak around 2052 cm-1 is attributed to γCN vibration of
SCN- ( Figure 3.1).

Figure 3.1. FT-IR spectra of KSCN, [Ph4P][Br], [Ph4P][SCN], [Ph4P]5[Dy(SCN)8].
[Ph3PBn]5[Dy(SCN)8], pale yellow solid. Yield, 81%. Mp: 50-52 0C.

1

H NMR (400

MHz, DMSO-d6), δ (ppm): 7.89 (t, 3H, J=8Hz), 7.56 (m, 6H), 7.45 (m, 6H), 7.33 (m, 2H), 7.23
(m, 2H), 7.13 (d, 1H), 5.23 (s, 1H), 5.21 (s, 1H).

13

C NMR (100 MHz, DMSO-d6), δ (ppm):

135.6, 135.5, 134.3, 131.3, 131.2, 130.6, 130.5, 129.3, 129.0, 128.4, 128.3, 118.7, 117.8, 80.0,
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28.8, 28.4. 31P NMR (101 MHz, DMSO-d6), δ (ppm): 24.0. IR (neat), ν (cm-): 2912, 2852, 2035,
1436, 1112, 724, 687. Anal. Calcd for C133H110DyN8P5S8: C, 66.72; H, 4.63; N, 4.68; S, 10.71.
Found: C, 66.01; H, 4.83; N, 4.21; S, 10.62.

Figure 3.2. FT-IR spectra of [Ph3PBn][Br], [Ph3PBn][SCN], [Ph3PBn]5 [Dy(SCN)8].
[Ph3PBnNO2]5[Dy(SCN)8], pale brown solid. Yield, 79%. Mp: 64-67 0C. 1H NMR (400
MHz, DMSO-d6), δ (ppm): 8.08 (d, 2H, J=8Hz), 7.91 (m, 2H), 7.75 (m, 13H), 7.26 (dd, 2H),
5.53 (s, 1H), 5.48 (s, 1H). 13C NMR (100 MHz, DMSO-d6), δ (ppm): 147.8, 136.6, 136.5, 135.8,
134.6, 134.5, 132.6, 132.5, 130.8, 130.7, 130.0, 124.3, 118.1, 117.3, 28.7, 28.2.

31

P NMR (101

MHz, DMSO-d6), δ (ppm): 24.5. IR (neat), ν (cm-1): 2921, 2846, 2042, 1439, 720, 689. Anal.
Calcd for C138H105DyN13P5S8: C, 60.99; H, 4.04; N, 6.95; S, 9.79. Found: C, 60.46; H, 3.95; N,
6.79; S, 9.73.
[Ph3PBnOEt]5[Dy(SCN)8], pale yellow solid. Yield, 72%. Mp: 45-48 0C. 1H NMR (400
MHz, DMSO-d6), δ (ppm): 7.89 (t, 3H, J=8Hz), 7.72 (m, 6H), 7.63 (m, 6H), 6.86 (dd, 2H), 6.73
(dd, 2H), 5.13 (s, 1H), 5.10 (s, 1H), 3.93 (q, 2H, J=8Hz), 1.26 (t, 3H, J=8Hz).

13

C NMR (100

MHz, DMSO-d6), δ (ppm): 158.9, 135.5, 134.6, 134.5, 132.5. 132.4, 130.6, 130.5, 129.9, 119.5,
119.4, 118.9, 118.0, 115.1, 28.2, 27.7, 15.0. 31P NMR (101 MHz, DMSO-d6), δ (ppm): 23.0. IR
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(neat), ν (cm-1): 2923, 2859, 2038, 1435, 1106, 722, 691. Anal. Calcd for C143H130DyN8O5P5S8:
C, 65.69; H, 5.01; 4.29; S, 9.81. Found: C, 66.58; H, 5.13; N, 4.20, S, 9.56.

Figure 3.3. FT-IR spectra of [Ph3PBnNO2][Br], [Ph3PBn NO2][SCN], Ph3PBnNO2]5[Dy(SCN)8].

Figure 3.4. FT-IR spectra of [Ph3PBnOEt][Br], [Ph3PBnOEt] [SCN], [Ph3PBnOEt]5[Dy(SCN)8].
The hydrophobic triphenylarylphosphonium cations confer poor water solubility to the
resulting phosphonium-dysprosium compounds, a feature useful in the synthesis of nanoparticles
by reprecipitation method. In contrast, K5Dy(SCN)8, a control compound containing a different
cation is much more water soluble, clearly demonstrating the role played by the cation in
dictating the solubilities of these compounds (Table 3.1). Resistivity of the saturated aqueous
solution of [Ph4P]5[Dy(SCN)8] was 14.58 Ω compared to 8.38 Ω for the control compound
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K5[Dy(SCN)8]. The high resistivity displayed by the phosphonium-dysprosium compounds
implies that they are stable and principally exist in a non-dissociated form in water.
Table 3.1. Solubility of phosphonium-dysprosium compounds in water*
Compound
Solubility (g/L) Solubility (mol/L) Dissociation constant
Ks (mol6/L6)
-5
[Ph3PBnNO2]5[Dy(SCN)8]
0.11
4.73e
3.50e-23
[Ph4P]5[Dy(SCN)8]

0.16

6.35e-5

2.05e-22

[Ph3PBn]5[Dy(SCN)8]

0.20

7.65 e-5

6.26e-22

[Ph3PBnOEt]5[Dy(SCN)8]

0.12

5.01 e-5

4.94e-23

K5Dy(SCN)8]

> 17

-

>> 1

* Reproduced from reference 19 with permission from Elsevier.
3.3.2. Physical and Morphological Properties of the Nanoparticles
The four compounds formed fairly spherical to slightly ovate nanoparticles of varying sizes
ranging from 21 nm to 92 nm (Figure 3.5) as determined by TEM.

Figure 3.5. Transmission electron micrographs of a) [Ph4P]5[Dy(SCN)8] nanoparticles, size: 54 ±
8nm b) [Ph3PBnOEt]5[Dy(SCN)8] nanoparticles, size: 65 ± 13 nm. c) [Ph3PBnNO2]5[Dy(SCN)8]
nanoparticles, size: 21 ± 3 nm and d) [Ph3PBn]5[Dy(SCN)8] nanoparticles, size: 92.3 ± 15.2 nm.
Bars represent 500 nm.
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The zeta potentials were determined to be -10 mV, -2 mV, -12 mV, and -6 mV for
[Ph4P]5[Dy(SCN)8],
[Ph3PBn]5[Dy(SCN)8],

[Ph3PBnOEt]5[Dy(SCN)8],

[Ph3PBnNO2]5[Dy(SCN)8],

and

respectively. The differences in the nanoparticles sizes and

corresponding zeta potentials clearly indicate the role played by the variations of the functional
groups on the phosphonium moiety of these ionic compounds. It is worth noting that the concept
in which the counterions influence the various properties of ionic compounds is in agreement
with previous studies.18
3.3.3. Magnetic Properties
The phosphonium-dysprosium compounds have a magnetically active ion Dy3+ with a 4f9
electron configuration and display paramagnetism at room temperature. Their magnetic
susceptibilities were determined by use of a superconducting quantum interference device
(SQUID) magnetometer. Magnetization at 300 K was measured in the magnetic field range of 70,000 to 70,000 Oe. Molar magnetic susceptibilities of the nanoparticles at 300 K were
determined as 0.0301, 0.029, 0.0333, and 0.0298 cm3 mol-1 for [Ph4P]5[Dy(SCN)8],
[Ph3PBnOEt]5[Dy(SCN)8], [Ph3PBnNO2]5[Dy(SCN)8] and [Ph3PBn]5[Dy(SCN)8] respectively,
which are similar to values obtained previously for Dy3+.19,30 The effective magnetic moment
(μeff) for Dy3+ is reported as 10.48 μB.30 The μeff values were calculated from the slopes of the
fitted lines (Table 3.2). Phosphonium-dysprosium compounds exhibited weak anti-ferromagnetic
interactions as seen from their Curie-Weiss temperature (Table 3.2), confirming a lack of cluster
formation within solution.
In this study, both field scans at a given temperature and temperature scans at a given
field were performed. Figure 3.6, A, represents a plot of the field dependence of magnetization
(M) at 300 K for [Ph3PBnNO2]5[Dy(SCN)8] nanoparticles. Similar results were obtained for all
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the other nanomaterials and bulk phosphonium-dysprosium compounds. This shows a linear field
dependence of magnetization between -7 and +7 Tesla. Such behavior suggests paramagnetic
interactions for these materials at 300 K.
Table 3.2. Summary of magnetic properties of phosphonium-dysprosium compounds*
Compounds
χmola (cm3 mol-1) μeffb (μB) Θc (K)
[Ph3PBnNO2]5[Dy(SCN)8]

0.0453

10.4

-4.3

[Ph3PBnOEt]5[Dy(SCN)8]

0.0400

10.2

-4.4

[Ph3PBn]5[Dy(SCN)8]

0.0385

9.9

-3.7

[Ph4P]5[Dy(SCN)8]

0.0353

9.6

-3.1

a

Molar magnetic susceptibility. bEffective magnetic moment.
*Reproduced from reference 19 with permission from Elsevier

c

Curie-Weiss temperature.

Interestingly, the magnetic susceptibility χ measured at 0.2 T shows little temperature
dependence above ~ 80 K, as plotted in Figure 3.6, B. While constant susceptibility usually
suggests a small spin contribution, the nonlinear M vs. H curve obtained at 200 K (Figure 3.6, C)
indicated superparamagnetic (S-shaped) behavior of [Ph3PBnNO2]5[Dy(SCN)8]. Similar results
were obtained with the other nanoparticles.

Figure 3.6. Magnetic property of [Ph3PBnNO2]5[Dy(SCN)8]. a) Field dependence of molar
magnetization at 300 K. b) Temperature dependence of static molar magnetic susceptibility χmol
at a field of 1,000 Oe and c) field dependence of molar magnetization at 200 K.
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The bulk materials did not display this trend which may be attributed to the enhanced
phase coherence of the magnetic dipoles within the nanomaterials as compared to the bulk
material.31 Therefore, the magnetic properties of the bulk material19 were retained and enhanced
in the nanoparticle formulations. The improved magnetism may prove useful as an external
magnetic field may be used to direct the nanoparticles to tumors or diseased sites. 17
3.3.4. UV-Vis Absorption and Fluorescence Spectroscopy
Luminescence properties of the nanoparticles were studied to ascertain that the
dysprosium lanthanide moiety observed in the bulk material was retained in the nanoscale. All
four compounds and the corresponding nanoparticles displayed two characteristic luminescence
peaks (Figure 3.7) consistent with Dy3+ containing compounds.32
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Figure 3.7. Fluorescence emission spectra of the phosphonium based nanoparticles with
transition assignments for [Ph4P]5[Dy(SCN)8] (red), Ph3PBnOEt]5[Dy(SCN)8] (green),
[Ph3PBnNO2]5[Dy(SCN)8] (purple), and [Ph3PBn]5[Dy(SCN)8] (blue) in acetonitrile (1 mM),
λex = 365 nm.
The fluorescence peak around 483 nm (blue region) arises from 4f9 electron configuration
due to a transition from 4F9/2 to 6H15/2 while the peak around 573 nm (yellowish-green region) is a
result of 4F9/2 to 6H13/2 transition. The latter peak is the most intense, consistent with their
yellowish-green luminescence. Lanthanide ions are known to have very low absorption
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coefficients because transitions within their 4f subshells are partially forbidden.33 However, it is
possible for a lanthanide to be excited outside its region of absorption if there is an organic
antenna chromophore that can transfer energy to it. In addition, lanthanide ions are known to be
quenchers

of

triplet

states

which

mitigates

against

photobleaching.34

The

aryltriphenylphosphonium cations in the phosphonium–dysprosium compounds may have
functioned as sensitizers (antenna) and therefore activated Dy3+ through energy transfer.
Fluorescence emanating from Dy3+ may be useful for potential application as an imaging agent in
cancer cells.
3.3.5. Cell Studies
An MTS assay method was used to evaluate the effectiveness of the nanoparticles in
vitro. To compare the effect of nanoparticles towards normal and cancer cells, human breast
carcinoma cells (Hs578T), and normal human breast fibroblast cells (Hs578Bst) were utilized.
These cell lines are an interesting pair to study as they were both derived from the same patient.
Hs578T is epithelial in origin and was derived from a carcinosarcoma while Hs578Bst was
developed from a normal tissue bordering the tumor.35 Other cancer cell lines investigated
include hormone-independent human breast carcinoma cells (MDA-MB-231), human pancreatic
carcinoma cells (PANC-1), and human colorectal adenocarcinoma cells (HT-29). The
nanoparticle formulations of the phosphonium-dysprosium compounds were found to be fairly
non-toxic to the normal breast cell line in comparison with the breast cancer cell line (Figure
3.8).
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Figure 3.8. Cytotoxicity of a) [Ph4P]5[Dy(SCN)8], b) [Ph3PBnOEt]5[Dy(SCN)8], c)
[Ph3PBnNO2]5[Dy(SCN)8], and d) [Ph3PBn]5[Dy(SCN)8] nanoparticles against breast cancer
(Hs578T, red) and normal breast (Hs578Bst, blue) cell lines, 48 h incubation. All points are
mean ± s.d of triplicate wells of three independent experiments. *Statistically different from the
corresponding concentration for the same compound in Hs578T (P < 0.05).
In addition, the IC50 values revealed that the nanoparticle formulations were significantly
more effective towards cancer cell lines in comparison to the native compounds19, while
maintaining comparable non-toxicity towards the normal cell line (Table 3.3). Although this was
true for almost all the cell lines investigated, the greatest difference was observed for PANC-1
cell

line

where

the

IC50

was

lower

by

an

order

of

magnitude,

except

for

[Ph3PBnNO2]5[Dy(SCN)8].19 Consequently, the developed nanoparticles are more selective
towards the cancer cell lines, consistent with previous literature.18,28 The effectiveness of the
nanoparticle formulations could be a result of increased surface area for interaction between the
cells and the nanomaterials, allowing an increase in the amount of interaction occurring.
Nanoparticle formulations have also been described to decrease non-specific targeting, alter
drugs pharmacokinetic profiles, and increase drugs therapeutic indices.11 Furthermore,
nanoparticles are reported to achieve improved intracellular concentration with minimal toxicity
to normal cells.36
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Table 3.3. Summary of IC50 values for phosphonium-dysprosium nanoparticles and the bulk
materials.
Cell lines
IC50 (μM)
[Ph4P]5
[Ph3PBnOEt]5
[Ph3PBnNO2]5
[Ph3PBn]5
[Dy(SCN)8]
[Dy(SCN)8]
[Dy(SCN)8]
[Dy(SCN)8]
nps Bulk*
nps
Bulk*
nps
Bulk* Nps
Bulk*
Hs578Bst

164

>200

48

74

370

147

86

85

Hs578T

112

83

23

19

140

91

36

22

MDA-MB-231

5

121

8

28

152

141

11

194

HT29

5

251

58

86

169

303

74

85

PANC-1

68

>400

20

>450

208

>400

28

>400

* Adapted from reference 19 with permission from Elsevier
Clonogenic assay revealed that nanoparticles from the four compounds prevented colony
formation of MDA-MB-231 cancer cell lines when surviving cells were cultured with a low
dosage of the nanoparticles after treatment (Figure 3.9). Accordingly, phosphonium-dysprosium
derived nanoparticles may be good candidates for further investigations as possible
chemotherapeutic agents.

Figure 3.9. Clonogenic assay images of MDA-MB-231 breast cancer cells showing a) Colonies
formed from control wells and b) zero colonies formed in wells treated with 5 µM
[Ph3PBnNO2]5[Dy(SCN)8]. Similar results were obtained for all the other phosphoniumdysprosium nanoparticles.
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3.4. Conclusion
In summary, multifunctional nanoparticles derived from phosphonium dysprosium salts
were synthesized and evaluated for anticancer properties in vitro. The nanoparticles were
designed to possess luminescence and paramagnetic properties from dysprosium containing
anions, and cancer targeting properties from aryltriphenylphosphonium cations. The
multifunctional properties have been evaluated in this study, and the nanoparticles developed are
promising chemotherapeutic agents. This study has demonstrated that nanoparticle formulations
derived from phosphonium dysprosium salts through a simple, additive free reprecipitation
method are more selective towards cancer cell lines in comparison to normal cell lines. This
finding provides an alternative avenue to drug design and development that is simple and time
efficient.
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CHAPTER 4. MULTIMODAL STIMULI RESPONSIVE THERANOSTIC
NANOMATERIALS DERIVED FROM IRON (III) PTHALOCYANINE
DEOXYCHOLATE SALT
4.1. Introduction
Design of nanometer sized vehicles for stimuli responsive delivery of therapeutic agents
is extremely promising with respect to modern, evolving techniques developed for non-invasive
treatment of diseases. In recent years, substantial efforts have been made towards development
of engineered theranostic nanomaterials with multifunctional and multimodal characteristics that
are capable of simultaneous therapy and diagnosis.1-3 Nanotheranostics interact more effectively
with biological systems which permits early detection of diseases. High surface area-to-volume
ratio is a characteristic of nanoparticles that enable enhanced drug loading.1-3 Drug encapsulated
nanometric sized materials exhibit prolonged half-life due to improved circulation times within
the body as compared to early excretion of free drug molecules before achieving their desired
result.4 Additionally, incorporation of target specificity to nanoscale delivery vehicles through
response to external or internal stimuli enables administration of lower doses, thus reducing
associated side-effects.5
Superparamagnetic iron oxide nanoparticles, magnetite (Fe3O4) and maghemite (γFe2O3), are typically used magnetic nanoparticles which have found wide applications in
biomedicine due to their inherent biocompatibility.6 Iron oxide nanoparticles of dual
functionality such as magnetic and target specific,7 magnetic-fluorescent,8,9 magnetic-pH
sensitive10 as well as magnetic-temperature sensitive11 have also been reported. In most cases,
surface modification with site specific ligands via covalent attachments is needed for
incorporation of other desired functionalities into magnetic nanoparticles. For instance,
conjugation of a protein or antibody adds target specificity to magnetic nanoparticles which
improves contrast in MRI. This allows improved distinction between the site of interest and the
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surrounding region.12,13 Target specificity can also be incorporated by attaching a stimuli
responsive element such as pH8,9 or temperature sensitive polymers11 to magnetic nanoparticles.
Incorporation or conjugation of a fluorescent dye imparts fluorescent properties in combination
with magnetism.14 Magnetic-fluorescent nanoparticles have been designed in the form of coreshell nanostructures such as CdSe@Fe3O4 nanoparticles.15 Moreover, use of quantum dots also
overcomes challenges associated with photostability. Presence of manifold functionalities within
the same particle permits the performance of multiple therapies such as magnetic hyperthermia,
photoinduced hyperthermia, chemotherapy as well as imaging. This improves the effectiveness
of a treatment.5
Despite several advances, nearly all variations of multifunctional nanomaterials reported
so far involve multistep, sophisticated and elongated synthetic approaches for incorporation of
desired functionalities which inevitably result in low-yields and more expensive products. In this
study, we demonstrate a facile approach to synthesis of a new class of multifunctional
nanoparticles with magnetic, pH sensitive, and fluorescence properties based on the use of iron
phthalocyanine. Iron (III) phthalocyanine has been previously used to coat the surface of Fe2O3
nanoparticles in order to obtain better dispersion in organic solvents as well as increase their
antioxidative properties.16 Its derivatives have been used to design multilayered electrodes for
use as resistive switching memory.17 Phthalocyanines and phthalocyanine conjugated
nanoparticles have been widely investigated for application in photodynamic therapy,18 although
iron phthalocyanines are not known to be used for such purposes. In all of the above mentioned
studies, metal phthalocyanines have been used in combination with other materials in order to
improve their redox properties.17,18 However, to the best of our knowledge nanomaterials derived
directly from Iron (III) phthalocyanine or its derivatives and its influence on the magnetic
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properties attributed to its metallic core has not been explored. Moreover, the use of Iron (III)
phthalocyanine or its nanomaterials for therapeutic or diagnostic purposes has not been reported.
This study was designed to develop multimodal nanoparticles directly from organic salts
based on Iron (III) phthalocyanine and to determine their utility in theranostic applications.
Multidimensional nanomaterials allow combined pH responsive drug delivery to cancer cells, as
well as provide simultaneous imaging. Our studies reveal significantly high biocompatibility of
this new class of nanomaterials. Hence, herein we have tailored an existing molecule using an
extremely facile approach that demonstrated improved functionality upon nanoformulation for
combined stimuli responsive therapeutic and diagnostic uses.
4.2. Materials and Methods
4.2.1. Materials
Sodium deoxycholate (97%), Doxorubicin hydrochloride, methylene chloride, Iron (III)
phthalocyanine chloride, phosphate buffered saline, anhydrous tetrahydrofuran (THF), and
ethanol (spectroscopic grade) were purchased from Sigma Aldrich (Milwaukee, WI). Cell
viability MTT (3-[4, 5-Dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide) assay kit was
purchased from Promega Corporation (Madison, WI). Triply deionized water (18.2 MΩ·cm)
from an Elga model PURELAB ultra water filtration system (Lowell, MA) was used for all
experiments. A Branson 3510RDTH model bath ultrasonicator (335 W, 40 kHz frequency)
(Branson Ultrasonics Corporation, Danbury, CT) was used at room temperature for preparation
of nanomaterials. Normal human breast fibroblast cells (Hs578Bct, ATCC no. HTB-125) and
hormone-independent human breast carcinoma cells (MDA-MB-231) were obtained from the
American Tissue Culture Collection (ATCC, Manassas, VA) and grown to 90% confluence prior
to any experiments according to ATCC protocol.
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4.2.2. Synthesis of [Ptc][DC]
A biphasic ion-metathesis reaction was performed. Dark green Iron (III) phthalocyanine
chloride (PtcCl) dissolved in dichloromethane (DCM) was mixed with sodium deoxycholate
(NaDC) dissolved in water and stirred for 48 hours (Scheme 4.1). The ([Ptc][DC]) which is
soluble in DCM, was then washed repeatedly with water to remove NaCl byproduct. Presence of
both ions in the final product was determined by use of 1H NMR and electrospray ionization
(ESI) performed in positive and negative ion modes.

Scheme 4.1. Synthesis of Iron (III) phthalocyanine based pH sensitive organic salt [Ptc][Dc].
4.2.3. Synthesis and Characterization of the Nanomaterials
The [Ptc][DC] derived nanoparticles were synthesized using a reprecipitation approach.
In this method, 100 µL of 1 mM stock of the compound in THF was injected in 5 ml of
phosphate buffer at pH 7.4 under sonication. Nanoparticles were then allowed to age for half an
hour before further experimentation. TEM micrographs were obtained using an LVEM5
transmission electron microscope (Delong America, Montreal, Canada). The nanoparticles
dispersion (3 µL) were drop casted onto a carbon coated copper grid and allowed to air dry at
room temperature before TEM imaging.
4.2.4. UV-Vis Absorption and Fluorescence Spectroscopy
Absorbance measurements were performed using a Shimadzu UV- 3101PC, a UV-Visnear-IR scanning spectrophotometer (Shimadzu, Columbia, MD). Fluorescence studies were
performed using a Spex Fluorolog-3 spectrofluorimeter (model FL3-22TAU3); Jobin Yvon,
93

Edison, NJ). A 0.4 cm path length quartz cuvette (Starna Cells) was used for acquiring the
fluorescence and absorbance against an identical cell filled with water as the blank. Fluorescence
studies were performed with right angle geometry.
4.2.5. Magnetic Property Measurement
Magnetic properties of the bulk material and the lyophilized nanoparticles were
investigated using Magnetic Property Measurement System (Quantum Design). Field scans (-7 T
to +7 T) at a given temperature and temperature scans (0 to 300 K) at a given field were both
performed.
4.2.6. Drug Encapsulation in Nanoparticles
Two hundred microliters of 1 mM [Ptc][DC] prepared in THF was rapidly injected to 10
mL water solution containing 0.4 mg/mL doxorubicin under sonication. The nanoparticles with
the drug were sonicated for 30 min and then allowed to stand for 24 h for drug diffusion into the
nanoparticles to reach equilibrium. Drug loaded nanoparticles were then centrifuged at 2000 rpm
for 20 min and the supernatant separated and kept. The drug loaded nanoparticles were then
lyophilized and drug delivery was studied under varying pH environments. Doxorubicin stock
solution without nanoparticles was prepared at the same time as the ones with nanoparticles,
sonicated and left for 24 h after which the absorbance was measured and compared to the
absorbance of doxorubicin in the supernatant to determine the amount of drug encapsulated.
4.2.7. Cell Studies
Cytotoxicities of the synthesized drug free and drug loaded nanomaterials were
determined against breast cancer (MDA-MB-23) and normal breast (Hs578Bst) cell lines by use
of MTT assay kit, according to the manufacturer’s instructions. Briefly, in a 96-well plate, 5000
cells in 0.1 mL culture medium were seeded to each well and incubated at 37 ºC, in 5% CO2
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humidified atmosphere for adherence. After 24 h, the old culture medium was aspirated and
replaced with 0.1 mL of fresh culture medium containing 0-50 μM of the salt dissolved in 1%
DMSO. The cells were then incubated for 48 h at 37 ºC, in a 5% CO2 humidified atmosphere. At
the end of the incubation period, the cells were treated with 15 μL MTT dye solution and
incubated for 2 h. Subsequently, 100 μL of stop solution was added per well and incubated
overnight at room temperature. The plate was then shaken for 20 s and absorbance read at 570
nm with a reference wavelength of 650 nm using a micro plate spectrophotometer (Benchmark
Plus, Bio-Rad Laboratories, Hercules, CA, USA). Cell viability as a percentage was determined
by taking the ratio between absorbance of the treated and untreated (control) cells. For confocal
microscopy, cells were incubated with the test compound at a final concentration of 20 μM for
45 min. Cell images were acquired under an objective (x40) with a confocal laser microscope
(Zeiss 510 confocal microscope) equipped with an argon laser excited at 488 nm.
4.3. Results and Discussions
Ionic liquid chemistry was exploited in this work to incorporate various functionalities
into a given material using a simple materials design. The organic salt [Ptc][DC] was synthesized
from iron (III) phthalocyanine chloride ([Ptc][Cl]) and sodium deoxycholate (NaDC) using an
ion metathesis reaction (Scheme 4.1). This molecular design was implemented with the idea that
the iron (III) core of phthalocyanine would contribute the magnetic properties and deoxycholate
counteranion would impart pH sensitive properties. In addition, the strong absorption of
phthalocyanine in the near infrared (NIR) and visible regions would also contribute to the
absorption and fluorescence properties of these materials.
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4.3.1. Synthesis and Characterization of [Ptc][DC]
Successful incorporation of phthalocyanine cation and deoxycholate anion was
ascertained by electrospray ionization mass spectrometry, 1H NMR, and FT-IR, and gave results
consistent with expectations as follows:
Iron (III) phthalocyanine cation (MS, ESI+) m/z 568 (C32H16FeN8+), deoxycholate anion
(MS, ESI-) m/z 392 (C24H39O4-).
Iron (III) phthalocyanine cation. 1H NMR (400 MHz, DMSO-d6), δ (ppm): 7.81 (m, 8H),
7.16 (m, 8H). Deoxycholate anion. 1H NMR (400 MHz, DMSO-d6), δ (ppm): 4.45 (m, 1H), 4.20
(m, 1H), 3.76 (m, 2H), 2.19 (s, 1H), 2.50 (s, 1H) 1.63-1.14 (m, 24H), 0.90 (s, 3H), 0.88 (s, 3H),
0.57 (s, 3H).
The FT-IR spectra are displayed in Figure 4.1. Compared to the spectrum of the starting
material (Figure 4.1, A), Figure 4.1, B, has new peaks near 3000 cm-1 attributed to the
deoxycholate anion.

Figure 4.1. FT-IR spectrum of A) [Ptc][Cl] and B) [Ptc][DC].
4.3.2. Spectral Characterization of [Ptc][DC] Nanoparticles
Spectral properties of [Ptc][DC] nanoparticles in an aqueous medium (buffer pH 7.4)
reveals the presence of two characteristic bands of phthalocyanines (Figure 4.2). These are the
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intense and broad B-band lying in the UV region and a relatively less intense Q-band lying in the
near infrared region (NIR) peaking at ~718 nm. A broad fluorescence emission with a peak at
~500 nm was observed when excited at a wavelength of 400 nm. However, no fluorescence
emission was observed in the NIR region corresponding to absorption at 718 nm. This
observation is in agreement with the previous literature which suggest that Iron(III)
phthalocyanines are non-fluorescent in the NIR.19 Spectral properties of both phthalocyanine
based nanoparticles were slightly affected by variations in pH.

Figure 4.2. (A) Absorption spectra and (B) fluorescence emission spectra (λex=400 nm) of
[Ptc][DC] nanoparticles with varying pH.
4.3.3. TEM Studies of [Ptc][DC] Nanoparticles
Transmission electron micrographs (TEM) revealed formation of distinct spherical
nanoparticles of average size 15-20 nm for [Ptc][DC] at pH 7.4 (Figure 4.3). The distinctly
separated [Ptc][DC] nanoparticles, as observed under TEM, as well as their stability in the
colloidal state, was further supported by their fairly high zeta potential value (+21.6 mV). The
zeta potential remained constant with time pointing towards appreciable stability of this nanodispersion. Moreover, the high positive zeta potential of these nanoparticles may facilitate
adsorption on or penetration through the negatively charged cell membranes.20
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B

A

200 nm

Figure 4.3. TEM micrographs of [Ptc][DC] nanoparticles respectively at A) pH 7.4 and B) pH 6.
Magnetic nanoparticles possess an inherent tendency to agglomerate and are rapidly
cleared by macrophages of the mononuclear phagocyte system upon intravascular
administration.11 Therefore, several efforts have been made in order to prevent the nanoparticle
agglomeration at physiological pH through surface modification keeping into account their nontoxicity as well as other factors.21,22 Accordingly, the highly stable nanoparticle dispersion
obtained in our case is considered an important improvement in this direction achieved through
inherent characteristics of [Ptc][DC] nanoparticles, excluding the requirement for stabilization
through surface modification. At pH 6, nanoparticles were observed to coalesce and lose their
distinct shapes. Such pH sensitive behavior was ascribed to the presence of the deoxycholate
counteranion. The counteranion has a pKa value near pH 6.823 suggesting protonation of the
counteranion below this pH. Thus, at pH 6 the [Ptc][DC] salt is expected to decompose, leading
to destabilization of the nanoparticles.
4.3.4. Magnetic Properties of [Ptc][DC] Nanoparticles
Magnetic properties of the bulk material and the lyophilized [Ptc][DC] nanoparticles
were investigated. In this study, both field scans at a given temperature and temperature scans at
a given field were performed. Figure 4.4, A, represents a plot of the field dependence of
magnetization (M) at 300 K for bulk [Ptc][DC].
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Figure 4.4. Magnetic properties of [Ptc][DC] (A) bulk M vs H at 300 K, (B) nanoparticles M vs
H at 300 K, (C) nanoparticles χ vs T at 0.2 Tesla and (D) nanoparticles M vs H at 200 K.
Note that M initially increases with increasing field, then decreases after reaching a
maximum near xy Oe, and changes sign from positive at H < yz Oe to negative at H > yz Oe,
suggesting mostly diamagnetic behavior of [Ptc][DC] bulk. This behavior also indicates that
magnetic interactions in bulk [Ptc][DC] are highly field dependent. In contrast, the nanoparticle
form of [Ptc][DC] exhibits linear field dependence of magnetization between -7 and +7 Tesla as
shown in Figure 4.4, B. Such behavior suggests paramagnetic interactions at 300 K. Magnetic
susceptibility (χ) measured at 0.2 T shows little temperature dependence above ~ 60 K, as plotted
in Figure 4.4, C. While constant susceptibility usually suggests a small spin contribution, the
nonlinear M vs. H curve obtained at 200 K (Figure 4.4, D) indicated superparamagnetic (Sshaped) behavior of [Ptc][DC] nanoparticles.14
Thus, our studies reveal an interesting transition in magnetic behavior from [Ptc][DC]
bulk to [Ptc][DC] nanoparticles which might be attributed to the enhanced phase coherence of
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the magnetic dipoles within the nanomaterials as compared to the bulk material.14 This indicates
the potential utility of these nanoparticles for the desired applications as discussed earlier.
4.3.5. pH Responsive Properties of [Ptc][DC] Nanoparticles
The pH sensitive response of these nanoparticles was further investigated in order to
examine its potential utility for pH responsive drug release. Doxorubicin was encapsulated into
[Ptc][DC] nanoparticles and lyophilized. The lyophilized drug encapsulated nanoparticles were
then exposed to buffers at physiological (pH 7.4) and pH 5.5 (Figure 4.5, C). Release of
doxorubicin was monitored through changes in absorbance values of the drug in the supernatant
buffer system. It was observed that only 17% of doxorubicin was released in the first three hours
at the physiological pH 7.4. A 100% doxorubicin was released within the same time period at pH
5.5. Therefore [Ptc][DC] nanomaterials may be useful as stimuli responsive drug delivery
vehicles under slightly acidic environments such as are found in tumors and bacterial infections.
4.3.6. Cell Studies
Cytotoxicity of doxorubicin loaded nanoparticles towards a normal breast (Figure 4.5, A),
and breast cancer cell lines (Figures 4.5, B) was performed. Both cell lines were incubated with
drug free and doxorubicin loaded [Ptc][DC] nanoparticles for 48 hours and cell viabilities were
determined. It was observed that normal breast cells remained essentially unaffected by both
drug free and doxorubicin loaded nanoparticles with increasing concentrations of the
nanoparticles. However, with breast cancer cell lines a concentration dependent cell death ensued
with doxorubicin loaded nanoparticles, demonstrating 37% cell viability at the highest
concentration studied (48 µM). In contrast, drug free [Ptc][DC] nanoparticles did not
significantly inhibit cell proliferation even at the highest concentrations, indicating they are nontoxic.
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Figure 4.5. Cell viability studies of free [Ptc][DC] and doxorubicin loaded [Ptc][DC]
nanoparticles in (A) Hs578Bst (normal breast) and (B) MDA-MB-231 (breast cancer) cell lines.
(C) Release profile of doxorubicin from [Ptc][DC] nanoparticles with varying pH. (D) Confocal
microscopic image of MDA-MB 231 cells after 2 h incubation with Dox free [Ptc][Dc]
nanoparticles.
These studies indicate that this novel, yet simple, approach to developing multifunctional
pH sensitive nanoparticles may be used to provide stimuli responsive drug delivery to acidic
environments such as cancer cells and infected tissues. The inherent biocompatibility excludes
the need to induce biocompatibility through conjugation with more compatible polymers or
proteins.
A confocal microscopy image (Figure 4.5, D) was obtained for MDA-MB-231 cell line
after 2 h incubation with drug free [Ptc][DC] nanoparticles. This suggests the potential utility of
these nanoparticles for simultaneous imaging and therapy. Since the deoxycholate is a nonfluorescent moiety, the observed fluorescence was attributed to the phthalocyanine counterpart,
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thus exhibiting actual capability of these materials for theranostic applications. Most of the
existing multimodal theranostics involve conjugation of separate moieties attributing each
functionality, thereby leading to highly elongated synthetic procedures.1 Therefore, the one-pot
synthesis of the multifunctional theranostic nanomaterials as reported in this study is
advancement in design of theranostics.
4.4. Conclusions
In summary, this study reports a facile one-pot approach for synthesizing pH responsivemagnetic-fluorescent nanoparticles by use of ionic liquid chemistry. These materials demonstrate
nearly 100% cell viability at all concentrations in both normal and cancer cells studied,
suggesting their fairly non-toxic characteristics. The pH responsive drug release property of
these nanomaterials in actual cellular environment could be efficiently used for target specific
delivery of therapeutic agents to tumors and other acidic environments. Besides, the interesting
transition in magnetic properties switching from diamagnetic bulk material to paramagnetic
nanoparticles indicate their potential to be exploited for applications in targeted drug delivery
using an external magnetic field, magnetic hyperthermia as well as their possible utility as MRI
contrast agents. Confocal fluorescence microscopic images obtained with MDA-MB-231 cells
upon a short incubation period with [Ptc][DC] nanoparticles emphasize their application for
simultaneous fluorescence imaging along with therapy. Thus, when one considers the simple
synthetic approach to development of this new class of multimodal, multifunctional as well as
highly biocompatible theranostic nanoparticles, these materials should be extremely promising
candidates for use as stimuli responsive drug delivery systems.
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CHAPTER 5. IONIC LIQUID-BASED NANOMATERIALS FOR PH SENSING AND
CHEMOTHERAPY*
5.1. Introduction
Smart materials capable of applications as inexpensive sensing tools using a simple
colorimetric approach are highly desirable for analysis and diagnosis. One of the most important
rationale for this observation is that colorimetric detection techniques minimize the need for
more sophisticated instrumentation. Numerous nanoparticles have been developed for
colorimetric biosensing, including gold, silver, graphene oxide, and carbon nanotubes.1 Color
changes observed due to aggregation and disaggregation of these nanoparticles have also been
used as methods for detection of several biomaterials.1 For example, magnetic nanoparticles such
as Fe3O4 undergo color change due to the catalysis of peroxidase substrates.2,3 Aptamer-based
colorimetric sensors are also reported, where aptamer binding events are transformed into a
colorimetric response.4 Colorimetric detection of adenosine and cocaine has also been performed
using such sensors.4
The pH balance in mammalian tissues can be altered under several health conditions such
as cancer, chronic pulmonary diseases, and renal failure.5 The extracellular pH value usually lies
in the range of 5 - 7 under various pathological conditions. Certain bacterial infections also
produce an acidic environment where the pH may vary between 4.5 - 7.0.6 On the basis of this
observation, pH sensitive polymeric nanoparticles as well as nanoparticles embedded in pH
sensitive gel matrices have been designed for local delivery of antibiotics.6

*Part of this work was published by Das, S.; Magut, P. K. S.; de Rooy, S. L.; Hasan, F.; Warner,
I. M., Ionic liquid-based fluorescein colorimetric pH nanosensors. RSC Advances 2013, 3,
21054-21061 and is Reproduced by permission of The Royal Society of Chemistry
DOI:10.1039/C3RA42394H
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Tumors and cancerous tissues have been found to exhibit acidic pH values as compared
to normal tissues due to the production of lactic acid as well as hydrolysis of ATP in the hypoxic
regions of tumors.5 Thus, several pH responsive nanoparticles have been applied to stimuli
responsive drug delivery for tumors and cancerous sites7 through exploitation of their acidic
environment.
As pH is an important indicator for advancement of numerous diseases and biological
processes, development of smart nanomaterials for simple detection of pH using a colorimetric
approach, in combination with additional measurable pH dependent parameters, is highly
desirable. In this regard, various metal nanoparticles based colorimetric pH sensors have been
reported, including modification of gold or silver nanoparticles with DNA,8 protein antigens,9
and polymers.10 Although several nanomaterials have been designed toward this end, most of
these materials involve multistep and very sophisticated synthetic procedures. Thus, a facile, cost
efficient design in this direction would be extremely advantageous.
Room temperature ionic liquids (RTILs) have been applied to multiple analytical
techniques such as separation science, MALDI-MS, quartz crystal microbalance sensors, as well
as synthetic chemistry, as catalysts and solvents in electroanalysis.11 Due to their versatility,
several ionic liquids have been prepared using various combinations of ions in order to obtain
desired properties. For example, a recent communication reports an RTIL-based colorimetric
amine sensing on films.12 In another study, ILs have been synthesized using indicator dyes and
their pH sensitive properties have been investigated.13 A recent report describes the design of an
ionic liquid polymer gel-based barcode system derived from indicator dyes for determining the
pH of sweat generated during an exercise period.14 However, to the best of our knowledge,
nanosensors based on RTILs with pH dependent colorimetric and morphological response have
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not yet been reported. Optical nanosensors for a variety of sensing applications including pH,
which involve encapsulation of dyes in polymeric nanoparticles, have been developed by
Kopelman and co-workers.15 However, pH dependent colorimetric and size changes have not
been observed in such studies. Moreover, problems such as leaching and alteration of
photophysical properties are often encountered upon encapsulation of fluorophores.15 In recent
years, our group has introduced nanoparticles derived from a Group of Uniform Materials Based
on Organic Salts (GUMBOS), which are higher melting (solid phase) counterparts of ionic
liquids with much wider scopes of variations. We have reported functional, as well as
multifunctional nanoGUMBOS with various morphologies and spectral features.16-18
Herein, we report the synthesis, characterization, and pH dependent properties of two
novel

nanomaterials

based

on

RTILs

derived

from

fluorescein

(FL)

and

trihexyltetradecylphosphonium (TTP) ions of two different stoichiometries. The present study
involves development of nanosensors directly from a fluorophore in contrast to studies reported
in the literature where the fluorophore is either encapsulated or covalently linked to polymeric
nanoparticles.

15,19

The pH dependent optical and morphological properties of these nanosensors

suggest their potential utility for applications in detection, in vitro pathological applications, as
components for pH and size dependent chemical separation,20 as well as pH sensitive drug
delivery devices.21
5.2. Materials and Methods
5.2.1. Materials
Trihexyltetradecylphosphonium chloride, disodium fluorescein, tetrabutylphosphonium
chloride, benzyltriphenylphosphonium chloride, 4-nitrobenzyltriphenylphosphonium chloride
and tetraphenylphosphonium chloride were purchased from Sigma Aldrich and were used as
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received. Citric acid (Sigma Aldrich), sodium phosphate dibasic heptahydrate (Fisher Scientific),
and sodium phosphate monobasic monohydrate (Fisher Scientific) were used for the preparation
of universal buffer (pH 2.2 - pH 5.5)22 and phosphate buffer (pH 7.4). Triply deionized water
(18.2 MΩ cm), obtained from an Elga model PURELAB ultra water-filtration system, was used
for the preparation of all the solutions.
5.2.2. Synthesis and Characterization of Ionic Liquids
The [TTP]2[FL] IL was synthesized using an ion exchange reaction (Scheme 5.1, A) where
TTPCl was dissolved in dichloromethane (DCM) and mixed with Na2Fl dissolved in water.
A

B

Step 1

Step 2

Scheme 5.1. Synthesis of (A) [TTP]2[FL] and (B) [TTP][FL] ionic liquids
Phosphonium chloride and disodium fluorescein were taken in a molar ratio of 2:1.The mixture
was stirred for 48 h following which the two layers were separated. The DCM layers were
washed several times with water to remove the water soluble impurities. The organic layer was
dried over anhydrous sodium sulfate and the solvent was removed under reduced pressure. The
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synthesis of [TTP][FL] was accomplished in two steps (Scheme 5.1, B). In the first step,
monosodium fluorescein was synthesized by monoprotonation of Na2FL by stirring it in a buffer
of pH 5.23 In the second step, the sodium ion was exchanged with the TTP cation in a 1:1 molar
ratio using the same ion-exchange reaction described above. Both products were characterized
by 1H-NMR and electrospray ionization mass spectrometry. The formation of the 1:1 and 2:1
stoichiometries was confirmed by integrated 1H NMR.
5.2.3. Synthesis and Characterization of Nanomaterials from Ionic Liquids
Nanomaterials were synthesized from the ILs using a modified simple, additive-free
reprecipitation method similar to that used for organic nanoparticles.24,25 In a typical preparation,
250 µL of a 1 mM solution of GUMBOS precursor dissolved in ethanol was rapidly injected into
5 mL of triply-deionized water in an ultrasonic bath, followed by additional sonication for 2 min.
All solvents used in this study were filtered prior to nanoparticle preparation using 0.2 µm nylon
membrane filters. The particles were allowed a 15 min of equilibration time after preparation and
then characterized using different techniques.
The average particle size and size distribution of the prepared nanomaterials were
obtained by use of transmission electron microscopy (TEM). TEM micrographs were obtained
using an LVEM5 transmission electron microscope (Delong America, Montreal, Canada). The
nanoGUMBOS dispersion (1 µL) were drop casted onto a carbon coated copper grid and allowed
to dry in air at room temperature before TEM imaging. Dynamic light scattering (DLS) studies
for size determination of nanomaterials were performed using a Malvern Zetasizer, UK. Zeta
potentials of the nanomaterials were also determined using the same set up.
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5.2.4. Absorption and Fluorescence Studies
Absorbance measurements were performed using a Shimadzu UV- 3101PC, an UV-Visnear-IR scanning spectrometer (Shimadzu, Columbia, MD). Fluorescence studies were
performed using a Spex Fluorolog-3 spectrofluorimeter (model FL3-22TAU3); Jobin Yvon,
Edison, NJ). A 0.4 cm path length quartz cuvette (Starna Cells) was used for acquiring the
fluorescence and absorbance spectra against an identical cell filled with water as the blank.
Fluorescence studies were performed adopting a synchronous scan protocol with right angle
geometry. Fluorescence spectra were corrected for inner filter effects using a standard formula.26
Fluorescence anisotropy (r) is a measure of the average angular displacement of the
fluorophore between the absorption and subsequent emission of the photon and is given by the
formula:

The parameters

and

are the fluorescence emission intensity measured parallel and

perpendicular to the vertically polarized excitation, respectively.

is the grating factor included

to correct for the wavelength response for polarization of the emission optics and the detector. Its
given by the formula:

The parameters

and

are the fluorescence emission intensity measured parallel and

perpendicular to the horizontally polarized excitation.26 Fluorescence lifetime measurements
were performed at Horiba Jobin Yvon, NJ using time domain mode. A picoseconds pulsed
excitation source of 450 nm was used and emission was collected at 545 nm for [TTP]2[FL] and
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515 nm for [TTP][FL] with a TBX detector. The time correlated single photon counting
(TSCPC) mode was used for data acquisition with a resolution of 7 ps/channel.
5.2.5. Cytotoxicity Studies
Cytotoxicities of [TTP]2[FL] and [TTP][FL] nanomaterials were determined against
breast cancer (MCF-7, ATCC no. HTB-22, MDA-MB-231, ACC no. HTB-26) and normal breast
(Hs578Bst, ATCC no. HTB-125) cell lines using an MTT Assay kit (Promega Corporation,
Madison, WI, USA), according to the manufacturer’s instructions. Briefly, in a 96-well plate,
5000 cells in 0.1 mL culture medium were seeded to each well. After 24 h, the old culture
medium was removed and discarded and 0.1 mL of new culture medium containing 0-40 μM ILs
dissolved in 1% DMSO was introduced to the cells. The cells were then incubated for 48 h at 37
ºC, in 5% CO2 atmosphere. At the end of the incubation period, the cells were treated with 15 μL
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and incubated for 4 h.
After 4 h, 100 μL of the stock solution was added per well and incubated overnight. The plate
was shaken for 20 s and absorbance was then read at 570 nm with a reference wavelength of 650
nm using a micro plate spectrophotometer (Benchmark Plus, Bio-Rad Laboratories, Hercules,
CA, USA). Cell viability as a percentage was determined by taking the ratio between absorbance
of the treated cells and the absorbance of untreated (control) cells taken as 100%.
5.3. Results and Discussions
Aqueous solutions of disodium fluorescein (Na2FL) has been known to exhibit pH
sensitive spectral changes, which are attributable to the presence of different ionic forms of
fluorescein.23 However, to the best of our knowledge and as demonstrated in this study, Na2Fl is
not known to exhibit any significant pH dependent colorimetric response. Moreover, Na2FL is
highly soluble in aqueous medium, and, thus, nanoformulation is not possible.

111

Herein, hydrophobic salts of fluorescein were synthesized in two different
stoichiometries in combination with TTP counterions. The presence of both the ions was
determined by electrospray ionization mass spectrometry performed in positive and negative ion
modes. The 1H NMR results were as follows; [TTP][FL]: Dark orange sticky solid. Yield, 93%.
1

H-NMR (DMSO, 400 MHz): δ 7.95 (d, J= 8.32, 1H), 7.55 (m, 2H), 7.13 (d, J= 7.44 Hz, 1H),

6.57 (d, J= 9 Hz, 2H), 6.34 (s, 1H), 6.30 (d, J= 8.88 Hz, 2H), 2.15 (m, 8H), 1.45-1.23 (m, 48H),
0.85 (m,12H).
[TTP]2[FL]: Orange viscous liquid. Yield, 88%. 1H-NMR (DMSO, 400 MHz): δ 7.88 (d,
J= 6.92 Hz, 1H), 7.40 (m, 2H), 7.00 (d, J= 7.04 Hz, 1H), 6.57 (d, J= 9.12 Hz, 2H), 6.08 (m, 3H),
2.15 (m, 16H), 1.46-1.23 (m, 96H), 0.87 (m, 24H).
The bulky TTP cation not only induces hydrophobicity in the resulting salt but also drops
its melting point below or close to room temperature, resulting in the formation of fluorescein
based ILs. Hydrophobic properties were introduced in order to obtain fluorescein nanoparticles
with pH sensitive spectral properties. The initial idea was to achieve these properties when these
nanoparticles were suspended in aqueous medium for expansion of their applications as stimuli
responsive carriers for therapeutic agents; however, the synthesized nanodroplets unexpectedly
exhibited numerous pH sensitive effects, as well as potential therapeutic characteristics, which
may allow several applications of these new materials.
5.3.1. Physical Characterization of the ILs
Two ILs were synthesized using ion metathesis reactions in two different stoichiometric
ratios, yielding the salts [TTP]2[FL] and [TTP][FL]. [TTP]2[FL] was an orange viscous liquid at
room temperature, while the latter, [TTP][FL], was a dark orange sticky solid (Figure 5.1).
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A

B

Figure 5.1. Pictures of the compounds (A) [TTP][FL] and [B] [TTP]2[FL.
A variation in their viscoelastic properties was expected, since the presence of two bulky cations
leads to further frustrated packing,27 resulting in a lower melting IL. Thermogravimetric analyses
of these compounds suggested a fairly high decomposition temperature for both compounds.
[TTP]2[FL] was stable up to 348.6 oC, while [TTP][FL] exhibited a decomposition temperature
of 354.6 oC (Figure 5.2).
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Figure 5.2. Thermogravimetric analysis of (A) [TTP][FL] and (B) [TTP]2[FL].
5.3.2. Optical Properties of pH Dependent TTP Nanomaterials
Nanomaterials derived from the two fluorescein-based ILs through a reprecipitation18
technique produced contrasting pH dependent colorimetric responses. The [TTP] 2[FL]
nanodroplet suspension exhibited a red color in water whose inherent pH was 8.4 and in
phosphate buffer of pH 7.4. These nanodroplets displayed distinct color changes with further
variations of buffer pH (universal buffer)22 in the acidic region. In a buffer of pH 5.5, the
solution was orange, orange green at pH 4, and light green at pH 2.2 (Figure 5.3, a). However,
[TTP][FL] nanoparticles did not exhibit a significant color change as a function of changes in pH
value (Figure 5.3, b). A control experiment was also performed with the parent compound
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(Na2FL) at the same concentration, which displayed little or no pH dependent colorimetric
response (Figure 5.3, c).
Absorption spectra of [TTP]2[FL] nanodroplets revealed a 23 nm red-shift in unbuffered
water and a 40 nm red-shift in buffer of pH 7.4, as compared to the same concentration of the
parent compound (Na2FL) in the corresponding media. A red shift in the absorption spectrum of
a dye is usually attributed to head to tail type of stacking, often referred to as J-type
aggregation.18
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Figure 5.3. pH dependent color change of (a) [TTP]2[FL] nanodroplets, (b) [TTP][FL]
nanoparticles and (c) Na2FL in water (inherent pH 8.4) and buffers of different pH.
A gradual blue shift in absorption maxima was observed with a lowering of the pH value
below 7.4 (Figure 5.4, a). In spite of this blue shift in acidic buffers, the absorption maxima of
the nanomaterials were red-shifted as compared to the parent compound. This observation
suggests J-type aggregates of various stacking angles in different pH environments, which results
in variable red-shifts.28 In order to further confirm this as an aggregation effect and not just the
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inherent characteristic of this IL, concentration dependent absorption spectra were collected.
Examination of these spectra indicated that the absorption maxima were identical with those of
the parent compound (490 nm) in the micromolar region. A concentration dependent change in
shape and position of the absorption spectra and a complete red-shift in the absorption peak at
higher concentrations further confirmed this as an aggregation effect, and, thus, the red shift is
attributed to J-type of aggregation within these nanomaterials at higher concentrations.18
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Figure 5.4. (a, c) absorption and fluorescence spectra of [TTP]2[FL] and (b, d) of [TTP][FL],
respectively.
In addition to the observed colorimetric response, [TTP]2[FL] nanodroplets were also
observed to display a pH dependent fluorescence emission and excitation spectra. In water (pH
8.4) and pH 7.4 buffer, the fluorescence emission and excitation spectra of the [TTP] 2[FL]
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nanodroplets (50 µM) were red-shifted as compared to the parent compound (Na2FL) and to the
same compound ([TTP]2[FL]) at lower concentrations. In an acidic environment, the
fluorescence spectrum was gradually blue-shifted towards the monomeric region, also suggesting
a change in molecular stacking with pH (Figure 5.4).18,28 It is worth noting that the Stokes shift
of these nanomaterials was extremely low and, in some cases (at pH 7.4 and 5.4), nearly
resonance fluorescence was observed, which is a well-established signature of J-aggregation.18 In
addition to the red-shifted absorption spectra and the small Stokes shifts (Figure 5.4), Jaggregation was also confirmed by use of fluorescence lifetime measurements. Lifetime studies
suggested that in water and at pH 7.4, [TTP]2[FL] nanodroplets were found to be composed
entirely of a shorter lifetime component (73 ps) which is characteristic of J-aggregates as
compared to its lifetime of 4 ns in the monomeric state in water. The monomeric lifetime was
found to be similar to that of the parent compound in an aqueous medium.29 The relatively lower
fluorescence intensity of [TTP]2[FL] J-aggregates is attributed to the formation of higher order
aggregates which leads to quenching.30
Although, [TTP][FL] nanodroplets did not demonstrate any significant pH dependent
color change, shifts (Figure 5.4, d) and the appearance of distinct peaks/ shoulders in the
absorption spectra (Figure 5.4, b) with varying pH suggest a similar change in molecular
aggregation for various pH environments.18 The fluorescence emission maxima in water was
centered around the monomeric emission peak (513 nm), revealing that the predominant emitting
species were likely monomers, which is also complemented by a two component fluorescence
lifetime decay with 79% contribution from the monomer with a lifetime of 3.9 ns and 21%
contribution from a 109 ps component attributed to J-aggregates. The fluorescence emission
maxima of [TTP][FL] at all pH values being centered on 513 nm is consistent with the fact that
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the primary fluorescence emission was contributed by the monomeric component. The decrease
in fluorescence emission was however attributed to the formation of weakly fluorescent or nonfluorescent aggregates in various pH environments.
Thus, it can be summarized from the optical properties thus far that the presence of two
TTP cations favors J-aggregation to a greater extent compared to one TTP cation. The two bulky
TTP cations might force the two adjacent FL2- anions to stack in a head-to-tail fashion (Figure
5.5) in order to have minimum steric hindrance from each other. However, only one TTP cation
in [TTP][FL] allows the two FL- anions to mostly stack in a random fashion, therefore
resembling the monomeric species in their spectral behaviour, and partly stacking into head-totail manner (J-type of aggregates) (Figure 5.5, B).

Figure 5.5. Schematic representation of the type of aggregation in (A) [TTP]2[FL] and (B)
[TTP][FL].
Examination of data from photostability studies of [TTP]2[FL] nanoparticles indicated
extremely high photostability upon prolonged (2500 s) irradiation under maximum exposure
(Figure 5.6, a). The photostability of [TTP]2[FL] in ethanolic solution were found to increase
under similar conditions. Such an effect was also observed in previous studies and was attributed
to irradiation induced J-aggregation.31 We note that photostability of fluorescent nanomaterials is
an extremely important factor for determining sensor applicability in adverse conditions. Thus,
the observed enhanced photostability in solutions and extremely high (100 %) photostability of
the nanodroplets of these materials are considered an additional advantage of the materials.
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Fluorescence anisotropy (FA) studies of the [TTP]2[FL] nanodroplets (Figure 5.6, b) also suggest
a change in molecular aggregation with variation of pH, exhibiting negative and lower FA values
in water and at pH 7.4 where J-aggregation is maximum. FA was found to increase with
increasing acidity of the buffer, suggesting alteration in molecular stacking and formation of
different types of aggregates. J-aggregates have often been reported to demonstrate lower as well
as negative FA upon excitation at a wavelength blue to J-band, and are attributed to faster
exciton relaxation and energy migration compared to randomly oriented or H-type of
aggregates.18,32

Figure 5.6. a) Photostabilities of [TTP]2[FL] nanoparticles compared to Na2FL solution in water
and b) fluorescence emission anisotropy of [TTP]2[FL] nanodroplets in buffer of varying pHs.
Fluorescence anisotropy studies provide a molecular level picture of the nanodroplets,
and a better understanding of the intermolecular aggregation behavior under various pH
conditions.
5.3.3. Morphological Changes in TTP Nanomaterials with Changes in pH
The pH dependent colorimetric response was also accompanied by a change in particle
size, as illustrated in the transmission electron microscopic images (Figure 5.7) of the
[TTP]2[FL] nanodroplets. These nanodroplets demonstrated a size of 28 ± 8 nm at pH 7.4,
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gradually increasing in size with lowering of pH, attaining a size of 1.6 ± 0.2 μm µm at pH 4,
followed by the appearance of two distinctly different sizes at pH 2.2 viz. 797 ± 171 nm, 167 ±
46 nm (Figure 5.7). This observation was also complemented by data obtained from DLS (Table
5.1). Examination of data from DLS studies indicated similar expansion of the nanodroplets with
decreasing pH up to pH 4, followed by a sudden drop in size at pH 2.2 accompanied with some
micron sized particles. It was noted during these studies that the nanodroplet dispersions were
extremely stable for hours with insignificant particle growth or change in surface charge over
time.

A

200 nm

B

100 nm

C

D

1 µm

1 µm

Figure 5.7. TEM micrographs of [TTP]2[FL] nanoparticles in (A) water (pH 8.4) (28 ± 8 nm nm)
and buffers of (B) pH 5.4 (453 ± 197 nm), (C) pH 4.0 (1.6 ± 0.2 μm), (D) pH 2.2 (797 ± 171 nm,
167 ± 46 nm).
Examination of TEM micrographs indicates relatively less dense mesodroplets in the
acidic environments which is recognized as an effect of expansion in these media. One possible
explanation for the observed nanoparticle swelling is attributed to an alteration in molecular
stacking within the nanodroplets under various pH conditions due to the formation of various
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protolytic states of FL. It has been reported in the literature that both covalent and non-covalent
interactions, such as π-π interaction, play a significant role in molecular organization at the
nanoscale level.33 Fluorescein is known to exist in four protolytic forms with dissociation
constants (pKa) of 2.08, 4.31 and 6.43 corresponding to respective transitions from cationic to
neutral, neutral to monoanionic, and monoanionic to dianionic.23
Table 5.1. Size of [TTP]2[FL] and [TTP][FL] nanodroplets at various pH values obtained from
dynamic light scattering.
System
Peak
1 Peak1 ar. Peak
2 Peak2 ar. Z-average PDI
(nm)
Int. (%)
(nm)
Int. (%)
(nm)
[TTP]2[FL]
85.8
100
77.1
0.144
in water
[TTP]2[FL]
173.9
100
188.3
0.18
in pH 7.4
[TTP]2[FL]
763
100
874
1
in pH 5.4
[TTP]2[FL]
1592
100
1592
1
in pH 4.0
[TTP]2[FL]
124.5
98.8
2490
1.2
114.7
0.141
in pH2.2
[TTP][FL]
100.7
100
96.62
0.088
in water
[TTP][FL]
534.7
100
538.1
0.039
in pH 7.4
[TTP][FL]
402.4
100
521.1
0.057
in pH 5.4
[TTP][FL]
795.9
100
717.4
0.17
in pH 4.0
[TTP][FL]
124.1
100
115.1
0.108
in pH2.2
The neutral to monoanionic and monoanionic to dianionic protolytic constants were
determined for [TTP]2[FL] using UV-visible spectrophotometry, and were found to be 4.52 and
6.37, respectively. These values are very close to the reported values for disodium fluorescein.
Thus, the smallest particle size was obtained when fluorescein was in its dianionic form (water
and pH 7.4) within the [TTP]2[FL] nanodroplets, which corresponds to an ordered head-to-tail
type of stacking, as suggested by the examination of the absorption and fluorescence steady state
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spectra, as well as time domain measurements. Monoprotonation of fluorescein at pH 5.4,
leading to its monoanionic form, disturbs this ordered arrangement, as suggested by shifts in the
absorption and fluorescence properties resulting in swelling. A further disordered arrangement
ensues when the neutral form of fluorescein is formed at pH 4, which in combination with the
hydrophobic phosphonium cations, results in an additional increase in particle size. However, the
formation of cationic fluorescein at pH 2.2 should lead to repulsion with the phosphonium
cations, possibly causing complete deformation of the pre-existing particles and formation of
smaller particles of a different size distribution. Both fluorescein and phosphonium cations under
such conditions are obviously considered to be associated with other counterions present in the
buffer. The changes in ionic states of fluorescein with variation of pH values, affect the number
of TTP ions associated with each FL, as well as the ionic and other non-covalent interactions
within the particles. This change in interactions leads to different molecular orientations and
stacking within the nanomaterial which contributes to the color changes of the dispersion.
Examination of zeta potential measurements indicates a systematic change in surface
charge with varying pH. The variation in molecular orientation at various pH values possibly
contributes to the variable surface charge. In water and at pH 7.4, the surface charge was highly
positive (~ +40mV) (Table 5.2), which is also consistent with the observed high stability of these
particles. The surface charge becomes less positive with lower pH values and then becomes
negative. The surface charge is nearly zero at pH 4 and attains a high positive value at pH 2. The
change in zeta potential (Table 5.2) of the particles at different pH values may also indicate
altered orientations and the presence of variable numbers of TTP ions associated with different
ionic forms of FL. A highly positive zeta potential at pH 2.2 is attributed to the presence of both
fluorescein and phosphonium cations under such conditions. Similarly, a very small value of zeta
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potential at pH 4 can be attributed to the presence of neutral fluorescein at this pH. In addition,
the presence of monoanionic FL at pH 5.5, where one TTP cation is associated with one FL,
yields a net negative surface charge. However, two TTP cations associated with the dianionic FL
present at a physiological pH results in a net positive surface charge. Thus it is the molecular
orientation and the presence of various ionic forms of FL under various pH conditions which
determine the net charge on the nanoparticles.
Table 5.2. Zeta potential of [TTP][FL] and [TTP]2[FL] nanodroplets at various pH values.
Ionic liquid
pH
Zeta potential (mV)
[TTP]2[FL] in water

8.4

+45.50

[TTP]2[FL]

7.4

+36.45

[TTP]2[FL]

5.4

-9.89

[TTP]2[FL]

4.0

+1.45

[TTP]2[FL]

2.2

+55.9

[TTP][FL] in water

8.4

+25.1

[TTP][FL]

7.4

-12.35

[TTP][FL]

5.4

-12.00

[TTP][FL]

4.0

+0.09

[TTP][FL]

2.2

+60.15

In addition to these two ILs, four other phosphonium based disubstituted and
monosubstituted ILs were synthesized through ion-exchange with the tetrabutylphosphonium,
benzyltriphenylphosphonium, 4-nitrobenzyltriphenylphosphonium, and tetraphenylphosphonium
counterions and their pH dependent characteristics were studied. A pH dependent color change
was not observed for any of these ILs, including the parent sodium salt. Thus, the observed pH
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dependent properties appear to be a unique characteristic of the nanoparticles based on
[TTP]2[FL].
5.3.4. Anticancer Activity of TTP-based ILs
The extracellular pH of tumors is acidic (pH 4-6) as compared to normal cells. This is
typically attributed to the lower buffering capacity of interstitial fluids and increased production
of lactic acid within cancer cells.5 Several pH sensing techniques including
spectroscopy (using inorganic phosphates), pH sensitive

19

13

P NMR

F resonance, pH sensitive 1H NMR

using appropriate probes, and pH sensitive Gadolinium relaxation using Gd based contrast agent,
have been reported for probing such environments.5 Incubation of [TTP]2[FL] nanoparticles in
acidified aqueous medium (with HCl) to pH 4 for an hour followed by removal of the solvent,
indicated carboxylic acid protons (via NMR) in deuterated DMSO (Figure 5.8). Acidified
aqueous medium was selected for these studies instead of buffer in order to avoid interferences
from carboxylic acid protons present in the salts constituting the buffer. This study indicates the
possible application of these particles in detecting acidic environments such as tumors by use of
1

H NMR as well.

Figure 5.8. NMR of [TTP]2[FL] nanodroplets synthesized and incubated at pH 4.
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As discussed earlier, the reported anticancer activity of some phosphonium based ionic
liquids34,35 suggested exploration of the same for these new phosphonium salts.
Tetraphenylphosphonium salts have been found to selectively accumulate in the mitochondrial
membrane of cancer cells which is considered the possible pathway for their anticancer
activities.35 Anticancer activity of these salts were also found to correlate with the chain length of
alkyl substitution on the phosphonium cation.34 Cytotoxicity of the [TTP][FL] and [TTP]2[FL]
nanoparticles towards a normal breast cell line (Hs578Bst) and two breast cancer cell line
(MCF7 and MDA-MB-231) were studied. Examination of data from these studies showed that
[TTP]2[FL] were more cytotoxic toward cancer cell lines as compared to [TTP][FL] (Figure 5.9).
Since [TTP]2[FL] leads to greater cell death in the studied cancer cells, this possibly signifies
that the phosphonium cation is primarily responsible for cytotoxic effects against cancer cells. In
addition, the IC50 values of the two compounds reveal that they are fairly non- toxic to normal
cells and highly toxic towards cancer cell lines (Table 5.3).
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Figure 5.9. Cytotoxicity studies of (A) [TTP][FL] and (B) [TTP] 2[FL] in normal breast
(Hs578Bst) and breast cancer (MDA-MB-231, MCF-7) cell lines.
In order to confirm this finding, control studies were also performed with both starting
materials and it was observed that Na2FL did not display any concentration dependent cell death
in the investigated concentration range. In contrast, TTPCl did exhibit a concentration dependent
cell death although their IC50 were much higher than those of the ILs reported in this study
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(Table 5.3). Thus, it is reasonable to infer that the cation and anion combination play a
cooperative effect in the observed selectivity towards cancer cell lines.
Table 5.3. IC50 values of [TTP][FL], [TTP]2[FL] and the starting materials [TTP][Cl] and Na2FL
ILs in breast normal and cancer cell lines.
Cell line

IC50 [TTP][FL]

IC50 [TTP]2[FL]

IC50 [TTP][Cl] IC50 Na2FL

Hs578Bst

10.17

7.17

5.0

>50

MCF-7

0.84

0.8

12.82

>50

MDA-MB-231

1.19

0.84

17.06

>50

Examination of the results outlined above suggest potential applications of [TTP]2[FL]
nanoparticles for use as a therapeutic agent against breast cancer cell lines since its toxicity
toward these cell lines are quite high as compared to normal cells. Although anticancer activities
of some phosphonium and ammonium based ILs have been reported in the literature against
several categories of human tumors, most studies do not report their activity in normal cell
lines.34 Lower cytotoxicities of our reported nanomaterials in normal breast cell lines clearly
suggest their potential applicability in simultaneous detection and treatment of cancer.
Recently, several studies have demonstrated the challenge of delivering a requisite
amount of drug to tumor cells due to the extremely high porosity of such cells. Owing to their
high porosity, the rate of drug diffusion out of the tumors may be appreciably high as compared
to the rate of drug penetration into them.36 In this regard, the expansive properties of [TTP]2[FL]
nanomaterials under acidic environment may be considered an advantage for addressing this
challenging problem, since the diffusion of the expanded nanoparticles out of the tumors will
likely be relatively slower.
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5.4. Conclusions
In summary, two novel fluorescent pH dependent IL based nanomaterials have been
successfully synthesized and characterized. The pH dependent colorimetric response of
[TTP]2[FL] nanodroplets suggests possible applications of these materials for determination of
acidosis in vitro or in vivo as biosensor for cancer and bacterial infections. The change in size of
the nanodroplets with decrease of pH as suggested from the TEM and DLS studies may also be
exploited for pH dependent molecular recognition as well as pH dependent drug delivery
vehicles.37 Furthermore, appearance of the carboxylic acid proton in 1H NMR in an acidic
environment can also be used as an additional detection tool. The anticancer activity displayed
by these nanomaterials adds to the utility of their pH dependent colorimetric and morphological
changes and thus may be further used for treating certain specific types of cancers as suggested
from the results demonstrated in this study. Considerably large zeta potential of these
nanoparticles suggests that the nanoparticles are stable in solution. In addition, the alteration in
fluorescence properties with pH may also be utilized in fluorescence imaging to detect various
pathological conditions.
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CHAPTER 6. CONCLUSIONS AND FUTURE DIRECTIONS
The work presented and discussed in my dissertation covers two classes of materials that
differ only in their melting points, namely ionic liquids and a Group of Uniform Materials Based
on Organic Salts. While ILs melt below 100 °C, the GUMBOS counterparts widen this range to
between 25 °C to 250 °C. By developing these solid phase materials, we have been able to
expand applications of low melting salts without worrying about their state of matter. From ILs
and GUMBOS, new nanomaterials were developed, and interesting biomedical applications have
been elucidated and discussed in this dissertation. It is exciting to realize that these nanomaterials
have such broad applications that this work only explores and expounds on a very small fraction
of possible applications. Their tunability in properties such as photophysical properties, melting
points, solubility, magnetism, toxicity, just to name a few opens a new frontier of research in the
sciences. This work focusses mainly on biomedical applications of ILs and GUMBOS
The first chapter provides a brief overview of one application namely cancer, the ancient
group of diseases that has evaded man’s innovativeness in the quest for its cure. A brief
discussion on the approaches being explored in its treatment is provided. Secondly, a synopsis of
previous studies, and foundations on ionic liquids, GUMBOS, nanomaterials, absorbance, and
fluorescence among others, is provided. The various major analytical techniques employed in
this research are also discussed to help the reader get a grasp of the principles behind them.
The second chapter discusses the synthesis, characterization and application of
rhodamine 6G-based GUMBOS in the biomedical field. In particular, application of these
compounds in cancer research in vitro is widely explored. Rhodamines have been investigated
previously for utility as chemotherapeutic agents with observed toxicity to both normal and
cancer cells. However, this study demonstrates that apart from tuning physicochemical
properties, cytotoxicity is also varied by changing the counter anion on a rhodamine 6G
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compound. The nanomaterials developed from the hydrophobic ones of the synthesized
rhodamine 6G-based GUMBOS turned out to be non-toxic to an investigated breast normal cell
line and toxic to breast cancer cell lines. This study demonstrated that both the cation and anion
in a drug play an active and cooperative role in anti-tumor cell proliferation potential.
The third chapter introduces a new frontier in development of multifunctional
nanomaterials based on phosphonium containing cations and dysprosium containing anions.
Emboldened by the selectivity observed in the rhodamine based nanomaterials, we sought to
synthesize nanomaterials from our previously reported chemotherapeutic candidates.
Phosphonium-dysprosium derived nanoparticles were more effective than the bulk materials in
killing select cancer cell lines while maintaining non-toxicity to a normal cell line. In addition,
the nanomaterials retained the properties inherent in the bulk compounds such as paramagnetism,
fluorescence, and cancer targeting. Therefore, if the phosphonium-dysprosium compounds prove
to be useful as chemotherapeutic agents, the nanoformulation would improve its efficacy without
loss of multifunctional properties.
In the fourth chapter another class of multifunction nanomaterials synthesized from iron
(III) phthalocyanine chloride and sodium deoxycholate is discussed. These nanomaterials were
designed to exhibit magnetism and fluorescence from the iron (III) phthalocyanine moiety and
pH sensitivity from the deoxycholate. The resulting GUMBOS were non-toxic to both normal
and cancer cell lines. This chapter demonstrates that the synthesized nanomaterial decompose or
break apart in acidic environments which would be useful in releasing drugs at the target site.
Drug release data revealed that doxorubicin encapsulated nanoparticles led to cell death in vitro
while free nanoparticles did not. The pH responsive drug release property in actual cellar
environment points toward possible utility as drug delivery vehicles to diseased tissue known to
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be acidic. Besides, the paramagnetism may be useful in targeted drug delivery of these
nanomaterials using an external magnetic field.
The fifth chapter introduces the second application namely pH sensing using an ionic
liquid

based

sensor.

Ionic

liquids

and

IL

nanodroplets

were

synthesized

from

trihexyltetradecylphosphonium (TTP) cation and a fluorescein anion. The pH dependent
colorimetric response of [TTP]2[FL] nanodroplets suggests possible application in determination
of acidosis in vitro or in vivo as biosensor for cancer and bacterial infections. The nanodroplets
were also shown to expand at acidic pHs which may be improve retention if applied in the leaky
vasculature of cancer tissue. Overall, all the compounds and nanomaterials synthesized and
reported in this dissertation were fluorescent. This may allow utility as cellular probes in cancer
cells.
The works presented in my dissertation are in no way exhaustive but serve as a
springboard for further research. The hydrophobic rhodamine based compounds as well as all the
nanomaterials reported in subsequent chapters displayed selectivity toward investigated cancer
cell lines. More work need to be done to elucidate the mechanisms behind observed selectivity. It
is worth noting that various factors influence the effect of a drug towards a disease. In particular
factors such as drug resistance, cellular uptake, chemical structure of the drug, and
hydrophobicity greatly determine the final effect of the drug. These factors need to be
investigated further to establish their role in the reported works. In the case of nanoparticles, the
surface charge, size, and composition play a great role. This list is by no means exhaustive and
therefore this field is rich in terms of the many factors that need to be investigated before a
theory is formulated. Generally, nanoparticle cellular uptake is via different types of endocytosis.
Although we demonstrated improved uptake of nanoGUMBOS by a breast cancer cell line, the

132

actual mode of uptake was not investigated. This should be performed in the future to establish if
it is the main reason behind the selectivity. Another question that remains to be answered
through future work is whether the observed selectivity is a general trend for nanoGUMBOS
derived from cationic compounds. Hence, more nanoGUMBOS from different cationic
compounds should be investigated. Besides, it would be interesting to perform in vivo studies
with the reported nanoGUMBOS as theranostics as well as actual pharmacophores. Promising
results in vivo would edge nanoGUMBOS closer to the market which is the main goal of drug
discovery related work. A future direction for the pH responsive colorimetric nanosensors may
be actual fabrication of a hand held device that can be used in detection of diseased or infected
tissue.
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